



ICKSH 2024

2024 KOREAN SOCIETY OF HEMATOLOGY
INTERNATIONAL CONFERENCE
& KSH 65th ANNUAL MEETING

MARCH 28 - 30, 2024

GRAND WALKERHILL HOTEL, SEOUL, KOREA

PROGRAM BOOK



The Korean Society of Hematology

대한혈액학회

CONTENTS

Welcome Message	1
ICKSH2024 Organizing Committee	2
ICKSH2024 Executive Steering Committee	4
Program at a Glance	5
Floor Plan	14
General Information	16
Speaker and Chair Information	19
Social Program	20
Events	21
Sponsors/ Exhibition	22
Key Speakers	28
Daily Program	29
Poster List	55

WELCOME MESSAGE

Dear Colleagues and Friends,


On behalf of the organizing committee, it is our great pleasure to invite you to participate in the 2024 Korean Society of Hematology (KSH) International Conference & 65th Annual Meeting, hosted by KSH, from March 28 to 30, 2024.

Held every year since 2018, the ICKSH congress shares up-to-date information and provides a unique opportunity for world-class leaders in the field to debate vital and contentious issues in Hematology.

Our programs will include topics such as benign hematologic diseases, various types of hematologic malignancies, coagulation/thrombosis related disorders and transfusion medicine through plenary lectures, as well as scientific and educational sessions.

In addition, a variety of stimulating social programs have been planned so participants can enjoy the fascinating Korean culture and share our warm spirit of friendship.

We welcome your support and look forward to seeing you at ICKSH 2024 in Seoul, Korea!

A handwritten signature in black ink.

Seoklae Chae, MD., Ph.D.
Congress Chair
The Korean Society of Hematology

A handwritten signature in black ink.

Seongsoo Jang, MD., Ph.D.
President
The Korean Society of Hematology

ICKSH2024 ORGANIZING COMMITTEE

Congress Chair

Seoklae Chae
Dongguk University College of Medicine

Auditor

Deog Yeon Jo
Chungnam National University College of Medicine

Secretary-General

Seok Jin Kim
Sungkyunkwan University School of Medicine

Director of Scientific Committee

Dong Yeop Shin
Seoul National University College of Medicine

Editor-in-Chief

Hee Jin Huh
Dongguk University College of Medicine

Director of Legislation

Yoon Hwan Chang
Seoul National University College of Medicine

Research Director

Hyoung Jin Kang
Seoul National University College of Medicine

Director of Medical Policy

Jin Seok Kim
Yonsei University College of Medicine

President

Seongsoo Jang
University of Ulsan College of Medicine

Auditor

Kyoo Hyung Lee
University of Ulsan College of Medicine

Vice Secretary-General

Hyery Kim
University of Ulsan College of Medicine

Treasurer

Yong Park
Korea University College of Medicine

Director of Health Insurance

SungYong Kim
Konkuk University Department of Medicine

Director of International Cooperation

Jae Wook Lee
College of Medicine, The Catholic University of Korea

Director of Social Cooperation

Ho young Yhim
Jeonbuk National University Medical School

Director of Public Relations

Jihyang Lim
College of Medicine, The Catholic University of Korea

ICKSH2024 ORGANIZING COMMITTEE

Director of Education

Hyo Jung Kim
Hallym University College of Medicine

Director of Textbook

Sung-Hyun Kim
Dong-A University College of Medicine

Director of Medical Information

Joon Ho Moon
Kyungpook National University School of Medicine

Special Director

In-Suk Kim
Pusan National University School of Medicine

Director of Membership

Seong Hyun Jeong
Ajou University School of Medicine

Director of Society Cooperation

Jae-Sook Ahn
Chonnam National University Medical School

Special Director

Byung Sik Cho
College of Medicine, The Catholic University of Korea

ICKSH2024 EXECUTIVE STEERING COMMITTEE

Congress Chair

Seoklae Chae
Dongguk University College of Medicine

Secretary-General

Seok Jin Kim
Sungkyunkwan University School of Medicine

Scientific Program Committee Chair

Dong Yeop Shin
Seoul National University College of Medicine

Finance Committee Chair

Yong Park
Korea University College of Medicine

Public Relations Committee Chair

Jihyang Lim
College of Medicine, The Catholic University of Korea

President

Seongsoo Jang
University of Ulsan College of Medicine

Vice Secretary-General

Hyery Kim
University of Ulsan College of Medicine

Scientific Program Committee Vice-chair

Yoon Seok Choi
Korea University College of Medicine

International Cooperation Committee Chair

Jae Wook Lee
College of Medicine, The Catholic University of Korea





Public Relations Committee Vice-chair

Hee Sue Park
Chungbuk National University College of Medicine

PROGRAM AT A GLANCE Thursday, March 28, 2024

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
08:00-09:00	Registration			
08:50-09:00	Opening Remark			
09:00-10:15	JS01 Asian Hematology Session I - EBV-associated lymphoid malignancy	ES01 Histiocytic neoplasm	SS01 Exploring the utilization of innovative technologies	SS02 The unmet needs in CML - Overcoming the obstacles of the road to cure
	Prospective studies for NK/T-cell lymphoma in Asia (Seok Jin Kim, Korea)	Histiocytic neoplasm in pediatrics (Kyung-Nam Koh, Korea)	Elucidating the 3D chromatin landscape of pediatric B-cell acute lymphoblastic leukemia using Micro-C (Kajsa Paulsson, Sweden)	Molecular mechanism of primary TKI resistance in CML (Jerald Radich, USA)
	Chronic active EBV disease: Our challenge to elucidate the pathogenesis (Ayako Arai, Japan)	Histiocytic sarcoma (Sung Nam Lim, Korea)	Integrated RNA and protein profiling of B-cell acute lymphoblastic leukemia at single-cell level (Sungyoung Choi, Korea)	Targeting leukemic stem cells in CML (Mhairi Copland, UK)
	NK lymphoma genomics (Weili Zhao, China)	Pathologic characteristics of histiocytic and dendritic cell neoplasms (Sun Och Yoon, Korea)	Leveraging dysregulated signaling networks for therapeutic benefit in myeloproliferative neoplasm (Stephen T. Oh, USA)	The role of NGS to detect TKI resistance (Saeam Shin, Korea)
	Break			
10:15-10:30				

PROGRAM AT A GLANCE Thursday, March 28, 2024

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
10:30-11:15	PL01 Somatic mutations and clonal dynamics in human blood cells (Peter J. Campbell, UK)			
11:15-12:00	PS01 Lab-on-a-chip in hematology (Chong H. Ahn, USA)			
12:00-12:15	Break			
12:15-13:05	SY01 Satellite Symposium 01 - MM  <small>PHARMACEUTICAL COMPANIES OF Janssen-Johnson</small> Treatment of newly diagnosed multiple myeloma: Focus on daratumumab combination (Elena Zamagni, Italy)	SY02 Satellite Symposium 02 - PNH  The ultimate value of C5 inhibitors in the evolving treatment landscape of PNH (Sung-Hyun Kim, Korea)	SY03 Satellite Symposium 03 - AML  Treatment strategies for elderly AML with <i>FLT3</i> -mutation, entering the era of FLT3 Inhibitors (Naoko Hosono, Japan)	SY04 Satellite Symposium 04 - Lymphoma  Advances in the treatment paradigm with bispecific antibodies (Wendy Osborne, UK)
13:05-13:50	Poster Viewing 1			
13:50-15:20	OP01 Acute leukemia-1	OP02 Lymphoma	OP03 Hematopoietic stem cell transplantation & Cellular therapy	OP04 Laboratory hematology
15:20-15:30	Break			

PROGRAM AT A GLANCE Thursday, March 28, 2024

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
15:30-16:45	JS02 EHA-KSH Joint Symposium - Multiple myeloma	SS03 Wise perspective on new approaches in hemophilia	SS04 For the next generation CAR-T cells	SS05 Deepened understanding of AML using multi-omics approaches
	Dynamic assessment of risk in multiple myeloma (Meral Beksak, Türkiye)	Approaches to treat people with hemophilia: What's new and what's not? (Leonard A. Valentino, USA)	CD7 CAR-T therapy for treating hematological malignancies (Peihua Lu, China)	Navigating cancer complexities via single-cell omics and AI (Manoj Bhasin, USA)
	PET/CT for risk stratification in multiple myeloma (Joon Ho Moon, Korea)	Prospects and challenges of gene therapy for hemophilia (Alok Srivastava, India)	Development of a novel anti-CD19 CAR-T cells in B cell lymphoma (Dok Hyun Yoon, Korea)	Targeting the developmental heterogeneity of human acute myeloid leukemia (Shanshan Pei, China)
	Bone marrow inflammation in multiple myeloma (Tom Cupedo, The Netherlands)			
	Single-cell analysis in multiple myeloma (Sung-Soo Park, Korea)	Exploring personalized tailored hemophilia treatment: Tailoring treatment to individual needs (Jeong A Park, Korea)	CAR-T cells for treatment of T cell malignancies (Paul M. Maciocia, UK)	Mutational profile in Korean AML patients (Jae-Sook Ahn, Korea)
16:45-16:55	Break			





PROGRAM AT A GLANCE Thursday, March 28, 2024

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
16:55-18:10	SS06 Insights into lymphoma pathobiology	SS07 Profound understanding of diagnosis and therapy in MDS	SS08 Leukemogenesis in children and adults	ES02 Basics for trainees (Kor)
	Germinal center in the genesis of lymphomas (Laura Pasqualucci, USA)	Molecular alterations and clinical implications in MDS (Yasushi Miyazaki, Japan)	<i>RUNX1</i> -FPDMM natural history study at NIH (Pu Paul Liu, USA)	Overview of lymphoma classification (Tae-Jung Kim, Korea)
	Genomics of follicular lymphoma: Clinical implications? (Robert Kridel, Canada)	Recent advances and future therapeutic strategies in MDS (Guillermo Garcia-Manero, USA)	Clinical impact of <i>DDX41</i> mutations in myeloid neoplasms (Talha Badar, USA)	What's new in AML classification (Hee Sue Park, Korea)
	Distinct and overlapping features of nodal peripheral T-cell lymphomas exhibiting a follicular helper T-cell phenotype: A multicenter study emphasizing the clinicopathological significance of follicular helper T-cell marker expression (Jin Ho Paik, Korea)	Current diagnostic challenges in MDS (In-Suk Kim, Korea)	Discovery of new regulators in hematopoietic stem cells and malignancies (Dongjun Lee, Korea)	Recent update of MDS classification (Miyoung Kim, Korea)
18:10-18:30	Break			
18:30-19:30	Welcome Reception (Aston House)			

PROGRAM AT A GLANCE Friday, March 29, 2024

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
08:00-09:00	Registration			
09:00-10:15	JS03 ASH-KSH Joint Symposium - Ped-ALL	ES03 Leaps and hurdles in transfusion medicine (Kor)	SS09 Clonal hematopoiesis: What should we know?	SS10 Predictive biomarkers in multiple myeloma
	Pediatric and AYA ALL: Lessons learned from Children's Oncology Group clinical trials (Sarah K. Tasian, USA)	Comprehensive overview of cell-based artificial platelet production (Seung Yeob Lee, Korea)	Clonal hematopoiesis and aging (Siddhartha Jaiswal, USA)	The impact of immune profiling of T-cell and plasma cells on non-cellular immune therapy in myeloma (Nizar Jacques Bahlis, Canada)
	Multicenter trials investigating childhood acute lymphoblastic leukemia in South Korea (Hyery Kim, Korea)	Anti-CD38 and anti-CD47 delay timely transfusion (Hyungsuk Kim, Korea)	Clonal hematopoiesis: Implications for cell therapy (Adam S. Sperling, USA)	Single-cell techniques to characterize immune microenvironment in MM (Niels Weinhold, Germany)
	Dissecting the developmental origins of acute leukemia (Charles G. Mullighan, USA)			
	Unveiling precision medicine: RNA and DNA sequencing in targeted therapy for Korean pediatric leukemia (Myungshin Kim, Korea)	Reappraisal of transfusion-transmitted infections (Dae-Hyun Ko, Korea)	Clonal hematopoiesis and metabolic diseases (Sung Hee Choi, Korea)	The power of ONE: Immunology in the age of single cell genomics (Ido Amit, Israel)
10:15-10:30	Break			

PROGRAM AT A GLANCE Friday, March 29, 2024

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
10:30-11:15	PL02			
	How to win: Competitive strategies in the hematopoietic stem cell niche (Margaret Goodell, USA)			
11:15-12:00	Poster Viewing 2			
12:00-12:15	Break			
12:15-13:05	SY05 Satellite Symposium 05 - AML 	SY06 Satellite Symposium 06 - Lymphoma 	SY07 Satellite Symposium 07 - CML 	SY08 Satellite Symposium 08 - Lymphoma 
	Continued hope with ONUREG - A new maintenance therapy to treat AML (Esther Oliva, Italy)	Mogamulizumab: A new era in MF/SS management - Clinical evidence and practical consideration (Francine Foss, USA)	TKI treatment pattern and new therapy of CML (Qian Jiang, China)	The optimal treatment strategy for transplant-ineligible relapsed/refractory DLBCL (Kwai Han Yoo, Korea)
13:05-13:20	Break			
13:20-14:50	OP05 Acute leukemia-2	OP06 Multiple myeloma	OP07 Myeloid neoplasm & Bone marrow failure	OP08 Thrombocytopenia & Supportive care
14:50-15:05	Break			

PROGRAM AT A GLANCE Friday, March 29, 2024

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
15:05-16:20	JS04 Current interests in hematologic disease in Asia	SS11 Quality-of-life revisited	SS12 Novel approaches for diagnosis & treatment of acute lymphoblastic leukemia	ES04 Monoclonal gammopathies of clinical significance
	The journey of bone marrow transplantation at BachMai General Hospital (Han Viet Trung, Vietnam)	Palliative care for patients with leukemia (Min Sun Kim, Korea)	Novel approaches for diagnosis & treatment of acute lymphoblastic and myeloid leukemia (Michel Zwaan, The Netherlands)	AL cardiac amyloidosis (Darae Kim, Korea)
	Current situation of management of Non-Hodgkin lymphoma in the Republic of Armenia (Yervand Hakobyan, Armenia)	Long-term survivorship in hematologic malignancies (Shahrukh K. Hashmi, UAE)	The role of blinatumomab in the treatment of MRD negative B-ALL in adults (Mark R. Litzow, USA)	Nephrologist's perspective on monoclonal gammopathy of renal significance (Soon Hyo Kwon, Korea)
	The evolution of hemophilia treatment in Thailand (Darintr Sosoithikul, Thailand)	The importance of monitoring symptoms and quality of life in routine hematology practice (Fabio Efficace, Italy)	Revised WHO classification of ALL: New era of genetic diagnosis (Ari Ahn, Korea)	Monoclonal gammopathies of neurological significance (Ju-Hong Min, Korea)
16:20-16:35	Break			

PROGRAM AT A GLANCE Friday, March 29, 2024


TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
16:35-17:50		SS13 Advancing in knowledge of rare pediatric hematologic disorders	JS05 Asian Hematology Session II - AML	ES05 Principles of anticoagulation - All about blood clots (Kor)
		Clonal evolution of MDS/AML in patients with cancer predisposition syndromes (Kenichi Yoshida, Japan)	Epidemiology, risk stratification and treatment outcome in acute myeloid treatment: Taiwan experience (Hsin-An Hou, Taiwan)	Back to the basic: Coagulation pathway (Seonyang Park, Korea)
		Congenital and aquired thrombophilic conditions in children (Leonardo R. Brandão, Canada)	Advancement in leukaemia diagnostics: The role of next-generation sequencing (NGS) in acute myeloid leukaemia in Malaysia (Angeli Ambayya, Malaysia)	Pharmacology: Anticoagulants and reversal agents (Seo-Yeon Ahn, Korea)
		Management of rare pediatric lymphomas (Jae Wook Lee, Korea)	Determining fitness for treatments in older adults with AML (Byung Sik Cho, Korea)	Proper application of anticoagulation therapy on cancer associated thrombosis (Ho-Young Yhim, Korea)
17:50-18:30	Gala Reception (Vista Lobby)			
18:30-20:00	Gala Dinner (Vista Hall)			

PROGRAM AT A GLANCE Saturday, March 30, 2024


TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
07:30-08:00		Business Meeting		
08:00-09:00	Young Investigator Award Presentation			
09:00-10:15	ES06 Essential knowledge for optimal hematologic consultation (Kor)	SS14 Novel insights into pathogenesis of MPN	SS15 Immunotherapies for lymphomas non-benefited from CAR-T cell therapy	ES07 Basic genomics for clinical hematologists (Kor)
	Functional iron deficiency in cancer patients (Ik-Chan Song, Korea)	Myeloproliferative neoplasms and inflammation (Steffen Koschmieder, Germany)	Treatment options for relapsed/refractory Hodgkin lymphoma after brentuximab vedotin and PD-1 blockade (Alex F. Herrera, USA)	Genomic technologies for detecting structural variations in hematologic malignancies (Miae Jang, Korea)
	Assessment of neutropenia in hospitalized patients (Young Hoon Park, Korea)	Signaling contributing to the development of myelofibrosis: Beyond JAK/STAT (Douglas Tremblay, USA)	Aggressive B-cell lymphomas: Immuno-chemotherapies other than CAR-T cell therapies (Jason Westin, USA)	The role of NGS in hematologic malignancies (Young-Uk Cho, Korea)
	Perioperative consultation for the appropriate transfusion (Ka-Won Kang, Korea)	Clonal evolution in myelofibrosis (Sung-Eun Lee, Korea)	Extranodal NK/T cell lymphoma: The immunogenic tumor (Won Seog Kim, Korea)	Germline predisposition to hematologic malignancies (Sang Mee Hwang, Korea)
10:15-10:30	Break			
10:30-11:15	PAP01 Plenary Abstract Presentation			
11:15-11:45	Award Ceremony & Closing			

FLOOR PLAN



1F



B1



FLOOR PLAN



GENERAL INFORMATION

REGISTRATION

All participants are required to visit the Self-registration Kiosk to pick up their badge. Scan the QR code and staff will assist you to receive your name tag. Badges must be worn during all scientific sessions and social programs.

>> Location: Vista Lobby (B2)

>> Operation Hours: March 28 (Thu) 07:00 – 18:00
March 29 (Fri) 07:00 – 18:00
March 30 (Sat) 07:00 – 12:00

>> On-Site Registration Fees

Category	Domestic	Overseas
Non-Member	KRW 300,000	USD 200
KSH Member	KRW 200,000	
Fellow/Nurse/Researcher	KRW 100,000	USD 100
Student/Resident	KRW 50,000	

+ Registration fees include: Participation in all scientific sessions, exhibitions, lunch box during satellite symposiums, coffee breaks, conference kit, welcome reception and gala dinner.









+ Conference kits will be distributed at the Kit Desk (B2).
Please scan your name badge to receive the kit.
Each kit includes a congress bag, program book, abstract book.

GENERAL INFORMATION

LUNCH AND COFFEE BREAKS

+ Satellite Symposia

Before the session begins, please pick up a lunch box at the entrance of the session room. Lunch boxes will be provided only to those who tag their name badges.

Satellite Symposium	SY01	SY02	SY03	SY04
Date/ Time	March 28 (Thu), 12:15-13:05			
Place	Room 1	Room 2	Room 3	Room 4
Sponsored by	 <small>TRANSNATIONAL COMPANIES</small> <small>or Johnson & Johnson</small>			
Satellite Symposium	SY05	SY06	SY07	SY08
Date/ Time	March 29 (Fri), 12:15-13:05			
Place	Room 1	Room 2	Room 3	Room 4
Sponsored by	 Bristol Myers Squibb			

+ Coffee Breaks

Coffee and tea will be served during break times on each floor. Barista coffee and tea will be provided in the Grand Hall Lobby (KSH Event Hall, B1).

CERTIFICATES OF ATTENDANCE AND PRESENTATION

Your certificate of attendance can be downloaded from the ICKSH 2024 website after the conference. The certificate of presentation can be issued after the conference by email. Please send a request to the secretariat (icksh@icksh.org) with your name, affiliation, and presentation code.

GENERAL INFORMATION

CME CREDIT INFORMATION (KOREAN PARTICIPANTS ONLY)

일자별 최대 취득가능 평점 안내

구분	3월 28일 (목)	3월 29일 (금)	3월 30일 (토)
대한의사협회 평점	6점	6점	2점
내과 전공의 평점	2점		

* 내과 전공의 평점은 대회 기간 동안 3시간 이상 출석해야 2평점 인정됩니다.

출결 체크

등록대에서 수령한 명찰에 인쇄된 바코드를 리더기에 태그해 주시기 바랍니다.
(매일 대회장 입장 시 1회, 퇴장 시 1회 (총 2회) 태그 필수)

부분 평점 인정 기준 안내

체류 시간	평점	체류 시간	평점
1시간 미만	평점 인정 불가	4시간 이상 - 5시간 미만	4평점
1시간 이상 - 2시간 미만	1평점	5시간 이상 - 6시간 미만	5평점
2시간 이상 - 3시간 미만	2평점	6시간 이상	6평점
3시간 이상 - 4시간 미만	3평점		

PARKING

Free parking is available for all attendees. Kindly state the name of the conference 'ICKSH 2024' when you exit.

SPEAKER AND CHAIR INFORMATION

PREVIEW ROOM

Please submit your file to the Preview Room no later than 2 hours before your scheduled session. Our staff will help you to upload the presentation file to the server. Afterwards, you can check to see that your files function correctly in the given environment.

>> Location: IDA 2 (B1)

>> Operation Hours: March 28 (Thu) 07:00 – 18:00

March 29 (Fri) 07:00 – 18:00

March 30 (Sat) 07:00 – 12:00

- + The Preview Room is only intended for submitting and checking files (No personal or other internet use).
- + It is not recommended that you connect your personal laptop directly to the podium because it may cause errors.
- + If you need to connect your personal laptop due to unavoidable circumstances, please notify the staff in the Preview Room in advance (You must have a USB-C type adapter for MacBooks).

INVITED/ORAL PRESENTATION

Speakers should be present in the session room 10 minutes prior to the session time. Please keep the allocated time to avoid time delays.

POSTER PRESENTATION

Poster presentation speakers should be present in front of their posters at the designated time. After onsite reviews, the scientific committee will select the Best Posters and winners should attend to receive the awards at the Closing Ceremony on March 30 (Sat). Snacks and drinks will be provided during the Poster Session.

>> Date & Time: March 28 (Thu) 13:05 – 13:50

March 29 (Fri) 11:15 – 12:00

>> Location: Walker Hall (1F)

CHAIR GUIDELINES

- + Chairs are kindly requested to be in the room at least 10 minutes before the session.
- + Please run the session as scheduled for smooth progress. (Please assist the presenter in completing the presentation within the allotted time frame.)
- + If a speaker is absent or late, our staff in the session room will notify the chairs in advance.

SOCIAL PROGRAM

ICKSH 2024 OPENING REMARK

We warmly welcome our participants from all around the world.

>> Date & Time: March 28 (Thu), 09:00

>> Location: Room 1+2 (Vista Hall, B2)

WELCOME RECEPTION

We would be delighted to have you at the Welcome Reception. Join us for a drink and have some fun!

>> Date & Time: March 28 (Thu), 18:30-19:30

>> Location: Aston House

GALA DINNER

Join us for an unforgettable evening of excellent cuisine, exciting performances, and networking opportunities. Stop in early and enjoy the cocktail reception in the lobby before the Gala Dinner!

>> Date & Time: March 29 (Fri), 18:30-20:00 (Cocktail Reception from 17:50)

>> Location: Room 1+2 (Vista Hall, B2)

AWARD CEREMONY & CLOSING

We will wrap up ICKSH 2024 by congratulating our award winners.

>> Date & Time: March 30 (Sat), 11:40-11:45

>> Location: Room 1+2 (Vista Hall, B2)

EVENTS

EARLY-BIRD EVENT

Gifts will be given daily to up to 100 session participants on a first-come, first-served basis.

>> Date & Time: March 28(Thu) – March 30(Sat)

>> Location: Each Session Room

BOOTH STAMP EVENT

If you visit exhibition booths and complete the stamp sheet, gifts will be given.

>> Date & Time: March 28(Thu) – March 30(Sat)

>> Location: IDA Hall Lobby (B1)

KSH INSTAGRAM FOLLOW EVENT (KOREAN PARTICIPANTS ONLY)

Visit Instagram, "Like" and Follow the KSH, and Win Gifts!

>> Date & Time: March 28(Thu) – March 30(Sat)

>> Location: Grand Hall Lobby (KSH Event Hall, B1)

ATTENDEES SURVEY

Please submit the survey every day after the conference ends. You can get a coffee gift card.

>> Date & Time: March 28(Thu) – March 30(Sat)

>> Location: IDA Hall Lobby (B1)

SPONSORS



SPONSORS

GOLD



SILVER



SPONSORS

BRONZE



BORYUNG



EXHIBITION

B2

VISTA HALL


Registration Desk



No.	Company Name
D-1	BMS Korea
D-2	Roche Korea
D-3	Handok Inc.
D-4	AstraZeneca Korea
D-5	JANSSEN KOREA
D-6	KYOWA KIRIN KOREA
D-7	Novartis Korea
D-8	Astellas Korea

No.	Company Name
P-1	GC Pharma
P-2	Takeda Korea

EXHIBITION




No.	Company Name	No.	Company Name
G-1	MSD Korea	S-1	QuantaMatrix
G-2	YUHAN	S-2	Samsung bioepis
G-3	Pfizer Korea		
G-4	Otsuka		
G-5	Sanofi-Aventis		
G-6	abbVie		
G-7	AMGEN		
G-8	Celltrionpharm		

EXHIBITION

1F

WALKER HALL



No.	Company Name
B-1	IL-YANG PHARM
B-2	roche - diagnostics
B-3	Sysmex Korea
B-4	BeiGene Korea
B-5, B-6	JW PHARMACEUTICAL
B-7	Antengene Medicine Co.,Ltd.

No.	Company Name
B-8	Boryung Pharmaceutical Co.,Ltd
B-9	RECORDATI KOREA
B-10	PharmaEssentia Korea
B-11	Samyang Holdings Corp.
B-12	Dong-A ST
B-13	SK Plasma

KEY SPEAKERS

MARCH 28 (Thu)



[PL01] Plenary Lecture 01

10:30 - 11:15 | Room 1+2

Somatic mutations and clonal dynamics in human blood cells

Peter J. Campbell

Wellcome Sanger Institute, UK



[PS01] Presidential Symposium

11:15 - 12:00 | Room 1+2

Lab-on-a-chip in hematology

Chong H. Ahn

University of Cincinnati, USA

MARCH 29 (Fri)



[PL02] Plenary Lecture 02

10:30 - 11:15 | Room 1+2

How to win: Competitive strategies in the hematopoietic stem cell niche

Margaret Goodell

Baylor College of Medicine, USA



iCKSH 2024

2024 KOREAN SOCIETY OF HEMATOLOGY
INTERNATIONAL CONFERENCE
& KSH 65th ANNUAL MEETING

DAILY PROGRAM

March 28 (Thursday)

March 29 (Friday)

March 30 (Saturday)

DAILY PROGRAM Thursday, March 28

08:50-09:00

Opening Remark

Room 1
Vista Hall 1

09:00-10:15

[JS01] Asian Hematology Session I - EBV-associated lymphoid malignancy

Room 1
Vista Hall 1

Chairs Ki Seong Eom (College of Medicine, The Catholic University of Korea, Korea)
Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)

JS01-1 Prospective studies for NK/T-cell lymphoma in Asia

Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)

JS01-2 Chronic active EBV disease: Our challenge to elucidate the pathogenesis

Ayako Arai (St. Marianna University School of Medicine, Japan)

JS01-3 NK lymphoma genomics

Weili Zhao (Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China)

Discussion

09:00-10:15

[ES01] Histiocytic neoplasm

Room 2
Vista Hall 2

Chairs Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea)
Hyung Soo Choi (Seoul National University College of Medicine, Korea)

ES01-1 Histiocytic neoplasm in pediatrics

Kyung-Nam Koh (University of Ulsan College of Medicine, Korea)

ES01-2 Histiocytic sarcoma

Sung Nam Lim (Inje University College of Medicine, Korea)

ES01-3 Pathologic characteristics of histiocytic and dendritic cell neoplasms

Sun Och Yoon (Yonsei University College of Medicine, Korea)

DAILY PROGRAM Thursday, March 28

09:00-10:15

[SS01] Exploring the utilization of innovative technologies

Room 3
Grand Hall 1

Chairs

Young Kyung Lee (Hallym University College of Medicine, Korea)
Yoon Hwan Chang (Seoul National University College of Medicine, Korea)

SS01-1

Elucidating the 3D chromatin landscape of pediatric B-cell acute lymphoblastic leukemia using Micro-C

Kajsa Paulsson (Lund University, Sweden)

SS01-2

Integrated RNA and protein profiling of B-cell acute lymphoblastic leukemia at single-cell level

Sungyoung Choi (Hanyang University College of Medicine, Korea)

SS01-3

Leveraging dysregulated signaling networks for therapeutic benefit in myeloproliferative neoplasm

Stephen T. Oh (Washington University School of Medicine, USA)

09:00-10:15

[SS02] The unmet needs in CML - Overcoming the obstacles of the road to cure

Room 4
Art Hall

Chairs

Chul Won Jung (Sungkyunkwan University School of Medicine, Korea)
Hawk Kim (Gachon University College of Medicine, Korea)

SS02-1

Molecular mechanism of primary TKI resistance in CML

Jerald Radich (Fred Hutchinson Cancer Center, USA)

SS02-2

Targeting leukemic stem cells in CML

Mhairi Copland (University of Glasgow, UK)

SS02-3

The role of NGS to detect TKI resistance

Saeam Shin (Yonsei University College of Medicine, Korea)

10:15-10:30

Break

DAILY PROGRAM Thursday, March 28

10:30-11:15

[PL01] Plenary Lecture 01

Room 1+2
Vista Hall 1+2

Chair Seoklae Chae (Dongguk University College of Medicine, Korea)

Somatic mutations and clonal dynamics in human blood cells

Peter J. Campbell (Wellcome Sanger Institute, UK)

11:15-12:00

[PS01] Presidential Symposium

Room 1+2
Vista Hall 1+2

Chair Seongsoo Jang (University of Ulsan College of Medicine, Korea)

Lab-on-a-chip in hematology

Chong H. Ahn (University of Cincinnati, USA)

12:00-12:15

Break

12:15-13:05

[SY01] Janssen



Room 1
Vista Hall 1

Chair Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)

Treatment of newly diagnosed multiple myeloma: Focus on daratumumab combination

Elena Zamagni (IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy)

12:15-13:05

[SY02] AstraZeneca



Room 2
Vista Hall 2

Chair Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)

The ultimate value of C5 inhibitors in the evolving treatment landscape of PNH

Sung-Hyun Kim (Dong-A University College of Medicine, Korea)

DAILY PROGRAM Thursday, March 28

12:15-13:05

[SY03] Astellas



Room 3
Grand Hall 1

Chair Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea)

Treatment strategies for elderly AML with FLT3-mutation, entering the era of FLT3 Inhibitors

Naoko Hosono (University of Fukui, Japan)

12:15-13:05

[SY04] Roche



Room 4
Art Hall

Chair Sung-Soo Yoon (Seoul National University College of Medicine, Korea)

Advances in the treatment paradigm with bispecific antibodies

Wendy Osborne (Newcastle University, UK)

13:05-13:50

Poster Viewing 1

Walker Hall

13:50-15:20

[OP01] Acute leukemia - 1

Room 1
Vista Hall 1

Chairs Dae-Young Kim (Ewha Womans University College of Medicine, Korea)
Saeam Shin (Yonsei University College of Medicine, Korea)

OP01-1 The transcriptomic profiles of NPM1 mutated acute myeloid leukemia reveal distinct subtypes characterized by varying clinical outcomes
Joon Ho Moon (Kyungpook National University Hospital, Korea)

OP01-2 Leukemic stem cells in acute myeloid leukemia further refine treatment outcomes in ELN molecular risk groups
Ritu Gupta (All India Institute of Medical Sciences, India)

OP01-3 Azacitidine combined with novel flavonoid derivative GL-V9 demonstrated synergistic anti-leukemia effect in acute myeloid leukemia by targeting DDIT4/mTOR signaling
Jun Li (Institute of Hematology Southeast University, China)

DAILY PROGRAM Thursday, March 28

OP01-4 Exploring the genetic landscape of B-ALL: Upregulation of cell adhesion pathway in the high risk adult as compared to pediatric B-ALL patients
 Preity Sharma (All India Institute of Medical Sciences, India)

OP01-5 CD371 expression in B-lymphoblastic leukemia and its correlation with recurrent genetic abnormalities
 Sweta Rajpal (ACTREC, Tata Memorial Centre, India)

13:50-15:20 [OP02] Lymphoma

Room 2
 Vista Hall 2

Chairs Ho Sup Lee (Kosin University College of Medicine, Korea)
 Youngwoo Jeon (College of Medicine, The Catholic University of Korea, Korea)

OP02-1 Treatment patterns in patients with mantle cell lymphoma: Updated report of the Asia-Pacific multinational retrospective registry study
 Dok Hyun Yoon (Asan Medical Center, Korea)

OP02-2 Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies
 Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)

OP02-3 Prognostic value of end-of-treatment [18F]FDG PET/CT in newly diagnosed patients with primary central nervous system lymphoma who respond to first-line treatment with high-dose methotrexate-based regimen
 Hyungwoo Cho (University of Ulsan College of Medicine, Korea)

OP02-4 Efficacy of dexamethasone, L-asparaginase, ifosfamide, carboplatin, and etoposide in patients with relapsed/refractory peripheral T cell lymphoma
 Tong Yoon Kim (College of Medicine, The Catholic University of Korea, Korea)

OP02-5 Characteristics and outcome of post-transplant lymphoproliferative disease in children treated with low-dose chemotherapy over 20 years in a single hospital
 Hyery Kim (University of Ulsan College of Medicine, Korea)

DAILY PROGRAM Thursday, March 28

13:50-15:20

[OP03] Hematopoietic stem cell transplantation & Cellular therapy

Room 3
Grand Hall 1

Chairs

Sung-Hyun Kim (Dong-A University College of Medicine, Korea)
Jieun Uhm (Hanyang University College of Medicine, Korea)

OP03-1

Reduced GVHD incidence with post-transplantation cyclophosphamide in higher-risk myelodysplastic syndrome

Jin-Hee Han (University of Ulsan College of Medicine, Korea)

OP03-2

Effect of HLA mismatched on the prognosis of cord blood transplantation for childhood leukemia

Lu Liu (Children's Hospital of Soochow University, China)

OP03-3

Interleukin 6 polymorphisms 174 and 597: Impact on graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in childhood

Bernd Gruhn (Jena University Hospital, Germany)

OP03-4

Reduced 8-Gray versus standard 13.2-gray total dose of total body irradiation based myeloablative conditioning for allogeneic hematopoietic cell transplantation in pediatric acute lymphoblastic leukemia

Jae Won Yoo (College of Medicine, The Catholic University of Korea, Korea)

OP03-5

High plasmacytoid dendritic cell dose infusion correlates with better plasmacytoid dendritic cell reconstitution and lower incidence of viral infection after transplantation: A single-center study

Di Yao (Children's Hospital of Soochow University, China)

OP03-6

BCMA-specific induced pluripotent stem cells and their specific regulatory pathways to differentiate into rejuvenated antigen-specific memory CD8+ T cells

Joeeun Bae (Dana Farber Cancer Institute, USA)

DAILY PROGRAM Thursday, March 28

13:50-15:20

[OP04] Laboratory hematology

Room 4
Art Hall

Chairs

Sun-Young Kong (National Cancer Center, Korea)
Hyun-Young kim (Sungkyunkwan University School of Medicine, Korea)

OP04-1

Dynamic thrombocytopenia has a negative impact with distinctive genetic and immunologic features in patients with myelofibrosis

Tong Yoon Kim (College of Medicine, The Catholic University of Korea, Korea)

OP04-2

Ribosomal protein S4X functions as a novel suppressor for SCF complex-mediated ubiquitination of myeloid cell leukemia1 and beta-catenin

Satsuki Ryu (Tokushima Bunri University, Japan)

OP04-3

Targeted-NGS across the beta-globin gene cluster identifies multiple linkage disequilibrium patterns in north Indian non-transfusion dependent beta-thalassemia patients

Prashant Sharma (Research Block A, Postgraduate Institute of Medical Education and Research, India)

OP04-4

Novel insight into the role of HTLV-1 unsliced form of bZIP factor: Specific interaction with HS-1 associated protein X-1, preventing caspase9-dependent apoptotic pathway

Yuka Tanaka (Tokushima Bunri University, Japan)

OP04-5

Immune function of chimeric antigen receptor T cells quantitatively assessed via molecular imaging flow cytometry

Hiroshi Yasui (The Institute of Medical Science, The University of Tokyo, Japan)

15:20-15:30

Break

DAILY PROGRAM Thursday, March 28

15:30-16:45

[JS02] EHA-KSH Joint Symposium - Multiple myeloma

Room 1
Vista Hall 1

Chairs Jin Seok Kim (Yonsei University College of Medicine, Korea)
Meral Beksac (Ankara Liv Hospital, Türkiye)

JS02-1 Dynamic assessment of risk in multiple myeloma
Meral Beksac (Ankara Liv Hospital, Türkiye)

JS02-2 PET/CT for risk stratification in multiple myeloma
Joon Ho Moon (Kyungpook National University School of Medicine, Korea)

JS02-3 Bone marrow inflammation in multiple myeloma
Tom Cupedo (Erasmus MC Cancer Center, The Netherlands)

JS02-4 Single-cell analysis in multiple myeloma
Sung-Soo Park (College of Medicine, The Catholic University of Korea, Korea)
Discussion

15:30-16:45

[SS03] Wise perspective on new approaches in hemophilia

Room 2
Vista Hall 2

Chairs Eun Jin Choi (Daegu Catholic University School of Medicine, Korea)
Young Shil Park (Kyung Hee University College of Medicine, Korea)

SS03-1 Approaches to treat people with hemophilia: What's new and what's not?
Leonard A. Valentino (Rush University, USA)

SS03-2 Prospects and challenges of gene therapy for hemophilia
Alok Srivastava (Christian Medical College, India)

SS03-3 Exploring personalized tailored hemophilia treatment: Tailoring treatment to individual needs
Jeong A Park (Inha University College of Medicine, Korea)

DAILY PROGRAM Thursday, March 28

15:30-16:45

[SS04] For the next generation CAR-T cells

Room 3
Grand Hall 1

Chairs Seok-Goo Cho (College of Medicine, The Catholic University of Korea, Korea)
Je-Jung Lee (Chonnam National University Medical School, Korea)

SS04-1

CD7 CAR-T therapy for treating hematological malignancies

Peihua Lu (Lu Daopei Hospital, China)

SS04-2

Development of a novel anti-CD19 CAR-T cells in B cell lymphoma

Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)

SS04-3

CAR-T cells for treatment of T cell malignancies

Paul M. Maciocia (Cancer Research UK, UK)

15:30-16:45

[SS05] Deepened understanding of AML using multi-omics approaches

Room 4
Art Hall

Chairs Hyeoung-Joon Kim (Chonnam National University Medical School, Korea)
Myungshin Kim (College of Medicine, The Catholic University of Korea, Korea)

SS05-1

Navigating cancer complexities via single-cell omics and AI

Manoj Bhasin (Emory University, USA)

SS05-2

Targeting the developmental heterogeneity of human acute myeloid leukemia

Shanshan Pei (Zhejiang University, China)

SS05-3

Mutational profile in Korean AML patients

Jae-Sook Ahn (Chonnam National University Medical School, Korea)

16:45-16:55

Break

DAILY PROGRAM Thursday, March 28

16:55-18:10

[SS06] Insights into lymphoma pathobiology

Room 1
Vista Hall 1

Chairs Gyeong-Sin Park (College of Medicine, The Catholic University of Korea, Korea)
Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)

SS06-1 Germinal center in the genesis of lymphomas

Laura Pasqualucci (Columbia University, USA)

SS06-2 Genomics of follicular lymphoma: Clinical implications?

Robert Kridel (University Health Network, Canada)

SS06-3 Distinct and overlapping features of nodal peripheral T-cell lymphomas exhibiting a follicular helper T-cell phenotype: A multicenter study emphasizing the clinicopathological significance of follicular helper T-cell marker expression

Jin Ho Paik (Seoul National University College of Medicine, Korea)

16:55-18:10

[SS07] Profound understanding of diagnosis and therapy in MDS

Room 2
Vista Hall 2

Chairs Yoo Jin Kim (College of Medicine, The Catholic University of Korea, Korea)
Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)

SS07-1 Molecular alterations and clinical implications in MDS

Yasushi Miyazaki (Nagasaki University, Japan)

SS07-2 Recent advances and future therapeutic strategies in MDS

Guillermo Garcia-Manero (The University of Texas MD Anderson Cancer Center, USA)

SS07-3 Current diagnostic challenges in MDS

In-Suk Kim (Pusan National University School of Medicine, Korea)

DAILY PROGRAM Thursday, March 28

16:55-18:10 [SS08] Leukemogenesis in children and adults

Room 3
Grand Hall 1

Chairs Kyung Ha Ryu (Ewha Womans University College of Medicine, Korea)
Hoon Kook (Chonnam National University Medical School, Korea)

SS08-1 RUNX1-FPDMM natural history study at NIH

Pu Paul Liu (National Institutes of Health, USA)

SS08-2 Clinical impact of DDX41 mutations in myeloid neoplasms

Talha Badar (Mayo Clinic, USA)

SS08-3 Discovery of new regulators in hematopoietic stem cells and malignancies

Dongjun Lee (Pusan National University School of Medicine, Korea)

16:55-18:10 [ES02] Basics for trainees (Kor)

Room 4
Art Hall

Chairs Inho Kim (Seoul National University College of Medicine, Korea)
Jaewoo Song (Yonsei University College of Medicine, Korea)

ES02-1 Overview of lymphoma classification

Tae-Jung Kim (College of Medicine, The Catholic University of Korea, Korea)

ES02-2 What's new in AML classification

Hee Sue Park (Chungbuk National University College of Medicine, Korea)

ES02-3 Recent update of MDS classification

Miyoung Kim (University of Ulsan College of Medicine, Korea)

18:10-18:30 Break

18:30-19:30 **Welcome Reception**

Aston House

DAILY PROGRAM Friday, March 29

09:00-10:15

[JS03] ASH-KSH Joint Symposium - Ped-ALL

Room 1
Vista Hall 1

Chairs Keon Hee Yoo (Sungkyunkwan University School of Medicine, Korea)
Wendy Stock (University of Chicago, USA)

JS03-1 Pediatric and AYA ALL: Lessons learned from Children's Oncology Group clinical trials

Sarah K. Tasian (The Children's Hospital of Philadelphia, USA)

JS03-2 Multicenter trials investigating childhood acute lymphoblastic leukemia in South Korea

Hyery Kim (University of Ulsan College of Medicine, Korea)

JS03-3 Dissecting the developmental origins of acute leukemia

Charles G. Mullighan (St. Jude Children's Research Hospital, USA)

JS03-4 Unveiling precision medicine: RNA and DNA sequencing in targeted therapy for Korean pediatric leukemia

Myungshin Kim (College of Medicine, The Catholic University of Korea, Korea)

Discussion

09:00-10:15

[ES03] Leaps and hurdles in transfusion medicine (Kor)

Room 2
Vista Hall 2

Chairs Duck Cho (Sungkyunkwan University School of Medicine, Korea)
Jihyang Lim (College of Medicine, The Catholic University of Korea, Korea)

ES03-1 Comprehensive overview of cell-based artificial platelet production

Seung Yeob Lee (Jeonbuk National University Medical School, Korea)

ES03-2 Anti-CD38 and anti-CD47 delay timely transfusion

Hyungsuk Kim (Seoul National University College of Medicine, Korea)

ES03-3 Reappraisal of transfusion-transmitted infections

Dae-Hyun Ko (University of Ulsan College of Medicine, Korea)

DAILY PROGRAM Friday, March 29

09:00-10:15 **[SS09] Clonal hematopoiesis: What should we know?** Room 3
Grand Hall 1

Chairs Myung Geun Shin (Chonnam National University Medical School, Korea)
Hyun Kyung Kim (Seoul National University College of Medicine, Korea)

SS09-1 **Clonal hematopoiesis and aging**
Siddhartha Jaiswal (Stanford University School of Medicine, USA)

SS09-2 **Clonal hematopoiesis: Implications for cell therapy**
Adam S. Sperling (Dana-Farber Cancer Institute, USA)

SS09-3 **Clonal hematopoiesis and metabolic diseases**
Sung Hee Choi (Seoul National University College of Medicine, Korea)

09:00-10:15 **[SS10] Predictive biomarkers in multiple myeloma** Room 4
Art Hall

Chairs Chang-Ki Min (College of Medicine, The Catholic University of Korea, Korea)
Jeong Yeal Ahn (Gachon University College of Medicine, Korea)

SS10-1 **The impact of immune profiling of T-cell and plasma cells on non-cellular immune therapy in myeloma**
Nizar Jacques Bahlis (University of Calgary, Canada)

SS10-2 **Single-cell techniques to characterize immune microenvironment in MM**
Niels Weinhold (Heidelberg University, Germany)

SS10-3 **The power of ONE: Immunology in the age of single cell genomics**
Ido Amit (Weizmann Institute of Science, Israel)

10:15-10:30 **Break**

DAILY PROGRAM Friday, March 29

10:30-11:15

[PL02] Plenary Lecture 02

Room 1+2
Vista Hall 1+2

Chair Chuhl Joo Lyu (Yonsei University College of Medicine, Korea)

How to win: Competitive strategies in the hematopoietic stem cell niche
Margaret Goodell (Baylor College of Medicine, USA)

11:15-12:00

Poster Viewing 2

Walker Hall

12:00-12:15

Break

12:15-13:05

[SY05] BMS



Room 1
Vista Hall 1

Chair Je-Hwan Lee (University of Ulsan College of Medicine, Korea)

Continued hope with ONUREG - A new maintenance therapy to treat AML
Esther Oliva (Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Italy)

12:15-13:05

[SY06] Kyowa Kirin



Room 2
Vista Hall 2

Chair Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)

Mogamulizumab: A new era in MF/SS management - Clinical evidence and practical consideration
Francine Foss (Yale University School of Medicine, USA)

12:15-13:05

[SY07] Novartis



Room 3
Grand Hall 1

Chair Dong-Wook Kim (Eulji University School of Medicine, Korea)

TKI treatment pattern and new therapy of CML
Qian Jiang (Peking University People's Hospital, China)

DAILY PROGRAM Friday, March 29

12:15-13:05

[SY08] Handok



Room 4
Art Hall

Chair Hyeon-Seok Eom (National Cancer Center, Korea)

The optimal treatment strategy for transplant-ineligible relapsed/refractory DLBCL

Kwai Han Yoo (Gachon University College of Medicine, Korea)

13:05-13:20

Break

13:20-14:50

[OP5] Acute leukemia - 2

Room 1
Vista Hall 1

Chairs Jeong-Ok Lee (Seoul National University College of Medicine, Korea)
Sung Han Kang (University of Ulsan College of Medicine, Korea)

OP05-1 Efficacy and safety of low-dose venetoclax combined with voriconazole in patients with acute myeloid leukemia unfit for intensive chemotherapy
Meng Danchen (The First Affiliated Hospital of Anhui Medical University, China)

OP05-2 The microRNA miR-222 is overexpressed and regulates proliferation, differentiation and apoptosis pathways in paediatric acute myeloid leukemia
Christine Wilson (All India Institute of Medical Sciences, India)

OP05-3 Genetic characteristics and venetoclax efficacy in acute myeloid leukemia
Daehun Kwag (College of Medicine, The Catholic University of Korea, Korea)

OP05-4 Adverse clinical impact of RB1 gene deletions alone and with concurrent IKZF1 gene deletions in pediatric B-cell acute lymphoblastic leukemia
Gadha K Leons (All India Institute of Medical Sciences, India)

OP05-5 Prognostic impact of concurrent genetic deletions in IKZF1 and CDKN2 in adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia
So Yeon Park (College of Medicine, The Catholic University of Korea, Korea)

OP05-6 Molecular map of T-lineage acute lymphoblastic leukemia: Clinical implications
Anita Chopra (All India Institute of Medical Sciences, India)

DAILY PROGRAM Friday, March 29

13:20-14:50

[OP6] Multiple myeloma

Room 2
Vista Hall 2

Chairs

Yeung-Chul Mun (Ewha Womans University College of Medicine, Korea)
Sung-Hoon Jung (Chonnam National University Medical School, Korea)

OP06-1

Carfilzomib, lenalidomide, dexamethasone in the real-world Asian relapsed and/or refractory multiple myeloma patients - KMM2201 study

Ji Hyun Lee (Dong-A University College of Medicine, Korea)

OP06-2

Real-world effectiveness of ixazomib, lenalidomide, and dexamethasone (IRd) in Asian patients with relapsed/refractory multiple myeloma (RRMM)

Soo Chin Ng (Subang Jaya Medical Centre, Malaysia)

OP06-3

Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in real world patients with relapsed/refractory multiple myeloma: KMM2004 study

Do Young Kim (Pusan National University School of Medicine, Korea)

OP06-4

Bortezomib maintenance therapy in transplant-ineligible newly diagnosed multiple myeloma have major response to induction chemotherapy (KMM 174)

Jung Yeon Lee (College of Medicine, The Catholic University of Korea, Korea)

OP06-5

Impact of pretransplant measurable residual disease(MRD) using multiparametric flow cytometry(mFCM) and imaging (PET-CT scan) before autologous stem cell transplantation(ASCT) in multiple myeloma : Insights from tertiary centre In India

Rudra Nayan Swain (Post Graduate Institute of Medical Education and Research, India)

OP06-6

The efficacy of salvage second autologous hematopoietic stem cell transplantation in Korean patients with relapsed/refractory multiple myeloma in novel agent era: the KMM2301 study

Jongheon Jung (National Cancer Center, Korea)

DAILY PROGRAM Friday, March 29

13:20-14:50

[OP7] Myeloid neoplasm & Bone marrow failure

Room 3
Grand Hall 1

Chairs

Seong Hyun Jeong (Ajou University School of Medicine, Korea)
Ji Hyun Kwon (Chungbuk National University College of Medicine, Korea)

OP07-1

Efficacy & safety of momelotinib vs danazol in JAKi-experienced patients with myelofibrosis & anemia: Asian subgroup analysis of the MOMENTUM trial

Sung-Soo Yoon (Seoul National University College of Medicine, Korea)

OP07-2

Distinct molecular and cytogenetic profiles of myelodysplastic syndrome with bone marrow eosinophilia and basophilia

Yujin Jung (Seoul National University College of Medicine, Korea)

OP07-3

Clinical and molecular characteristics and prognostic significance of autoimmune disease in myelodysplastic syndrome

Yunsuk Choi (University of Ulsan College of Medicine, Korea)

OP07-4

Haploidentical HCT using ex vivo T cell-depleted PBSC as first-line therapy for pediatric patients with acquired SAA

Ho Joon Im (University of Ulsan College of Medicine, Korea)

OP07-5

STK10 mutation block erythropoiesis in acquired pure red cell aplasia via down-regulated the ribosome biosynthesis

Meng Danchen (The First Affiliated Hospital of Anhui Medical University, China)

13:20-14:50

[OP8] Thrombocytopenia & Supportive care

Room 4
Art Hall

Chairs

Junshik Hong (Seoul National University College of Medicine, Korea)
Seungmin Hahn (Yonsei University College of Medicine, Korea)

OP08-1

Clinical outcomes of TPO-receptor agonists in patients with steroid-refractory immune thrombocytopenia; Significant conditions of discontinuation with good response

Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea)

OP08-2

Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicenter observational retrospective study in China

Zhifa Wang (Beijing Children's Hospital, China)

DAILY PROGRAM Friday, March 29

- OP08-3** Effect of anagrelide on health-related quality of life in patients with treatment-naïve, high-risk essential thrombocythemia
Taekeun Park (Seoul National University College of Medicine, Korea)
- OP08-4** Impact of hematopoietic stem cell transplantation on bone metabolism and growth in pediatric patients with thalassemia major
Yu Liu (Shantou University, China)
- OP08-5** Effects of tertiary palliative care on the pattern of end-of-life care in patients with hematologic malignancies
Dong Hyun Kim (Seoul National University College of Medicine, Korea)
- OP08-6** The clinical manifestation, prognostic factors, and outcomes of adenovirus pneumonia after allogeneic hematopoietic stem cell transplantation
Yuewen Wang (Peking University People's Hospital, China)

14:50-15:05 Break

15:05-16:20 **[JS04] Current interests in hematologic disease in Asia**

Room 1
Vista Hall 1

Chair Byeong-Bae Park (Hanyang University College of Medicine, Korea)

JS04-1 The journey of bone marrow transplantation at BachMai General Hospital
Han Viet Trung (Bach Mai Hospital, Vietnam)

JS04-2 Current situation of management of non-Hodgkin lymphoma in the Republic of Armenia
Yervand Hakobyan (Armenian Hematology Association, Armenia)

JS04-3 The evolution of hemophilia treatment in Thailand
Darintr Sosoithikul (Chulalongkorn University, Thailand)

Discussion

DAILY PROGRAM Friday, March 29

15:05-16:20

[SS11] Quality-of-life revisited

Room 2
Vista Hall 2

Chairs Sung Yong Oh (Dong-A University College of Medicine, Korea)
Yong Park (Korea University College of Medicine, Korea)

SS11-1

Palliative care for patients with leukemia

Min Sun Kim (Seoul National University College of Medicine, Korea)

SS11-2

Long-term survivorship in hematologic malignancies

Shahrukh K. Hashmi (Mayo Clinic, UAE)

SS11-3

The importance of monitoring symptoms and quality of life in routine hematology practice

Fabio Efficace (Italian Group for Adult Hematologic Diseases, Italy)

15:05-16:20

[SS12] Novel approaches for diagnosis & treatment of acute lymphoblastic leukemia

Room 3
Grand Hall 1

Chairs Hyoung Jin Kang (Seoul National University College of Medicine, Korea)
Ho-Jin Shin (Pusan National University School of Medicine, Korea)

SS12-1

Novel approaches for diagnosis & treatment of acute lymphoblastic and myeloid leukemia

Michel Zwaan (Princess Máxima Center for Pediatric Oncology, The Netherlands)

SS12-2

The role of blinatumomab in the treatment of MRD negative B-ALL in adults

Mark R. Litzow (Mayo Clinic, USA)

SS12-3

Revised WHO classification of ALL: New era of genetic diagnosis

Ari Ahn (College of Medicine, The Catholic University of Korea, Korea)

15:05-16:20

[ES04] Monoclonal gammopathies of clinical significance

Room 4
Art Hall

Chairs Young Rok Do (Keimyung University School of Medicine, Korea)
Hyo Jung Kim (Hallym University College of Medicine, Korea)

ES04-1

AL cardiac amyloidosis

Darae Kim (Sungkyunkwan University School of Medicine, Korea)

DAILY PROGRAM Friday, March 29

ES04-2 Nephrologist's perspective on monoclonal gammopathy of renal significance
Soon Hyo Kwon (Soonchunhyang University College of Medicine, Korea)

ES04-3 Monoclonal gammopathies of neurological significance
Ju-Hong Min (Sungkyunkwan University School of Medicine, Korea)

16:20-16:35 Break

16:35-17:50 **[SS13] Advancing in knowledge of rare pediatric hematologic disorders** Room 2
Vista Hall 2

Chairs Ho Joon Im (University of Ulsan College of Medicine, Korea)
Hye Lim Jung (Sungkyunkwan University School of Medicine, Korea)

SS13-1 Clonal evolution of MDS/AML in patients with cancer predisposition syndromes
Kenichi Yoshida (National Cancer Center Research Institute, Japan)

SS13-2 Congenital and acquired thrombophilic conditions in children
Leonardo R. Brandão (University of Toronto, Canada)

SS13-3 Management of rare pediatric lymphomas
Jae Wook Lee (College of Medicine, The Catholic University of Korea, Korea)

16:35-17:50 **[JS05] Asian Hematology Session II - AML** Room 3
Grand Hall 1

Chairs Sangkyun Sohn (Kyungpook National University School of Medicine, Korea)
Byong Soo Kim (Korea University College of Medicine, Korea)

JS05-1 Epidemiology, risk stratification and treatment outcome in acute myeloid treatment: Taiwan experience
Hsin-An Hou (National Taiwan University, Taiwan)

JS05-2 Advancement in leukaemia diagnostics: The role of next-generation sequencing (NGS) in acute myeloid leukaemia in Malaysia
Angeli Ambayya (Ministry of Health, Malaysia)

DAILY PROGRAM Friday, March 29

JS05-3 **Determining fitness for treatments in older adults with AML**
Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea)
Discussion

16:35-17:50 **[ES05] Principles of anticoagulation - All about blood clots (Kor)**

Room 4
Art Hall

Chairs Soo-Mee Bang (Seoul National University College of Medicine, Korea)
Sung Hwa Bae (Daegu Catholic University School of Medicine, Korea)

ES05-1 **Back to the basic: Coagulation pathway**
Seonyang Park (Inje University College of Medicine, Korea)

ES05-2 **Pharmacology: Anticoagulants and reversal agents**
Seo-Yeon Ahn (Chonnam National University Medical School, Korea)

ES05-3 **Proper application of anticoagulation therapy on cancer associated thrombosis**
Ho-Young Yhim (Jeonbuk National University Medical School, Korea)

17:50-18:30 **Gala Reception**

VISTA Hall
Lobby

18:30-20:00 **Gala Dinner**

Room 1+2
Vista Hall 1+2

DAILY PROGRAM Saturday, March 30

07:30-08:00

Business Meeting

Room 2
Vista Hall 2

08:00-09:00

[YI] Young Investigator Award Presentation

Room 1
Vista Hall 1

Chairs

Deog-Yeon Jo (Chungnam National University College of Medicine, Korea)
Je-Hwan Lee (University of Ulsan College of Medicine, Korea)

YI-1

Comparison of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCY) for the prevention of graft-versus-host disease in allogeneic hematopoietic stem cell transplant patients who achieved complete remission after induction therapy for acute myeloid leukemia
Hyunkyung Park (University of Ulsan College of Medicine, Korea)

YI-2

Evaluation of plasma cell sorting methods in multiple myeloma patients: Flow cytometry versus magnetic beads
Saeam Shin (Yonsei University College of Medicine, Korea)

YI-3

Comparative analysis of genes according to ropeginterferon alfa-2b treatment response in patients with polycythemia vera
Seug Yun Yoon (Soonchunhyang University College of Medicine, Korea)

YI-4

Single-cell transcriptome analysis to investigate the immune profile of T cells post-allogeneic hematopoietic stem cell transplantation and elucidate mechanisms underlying graft-versus-host disease
Jong Hyuk Lee (College of Medicine, The Catholic University of Korea, Korea)

YI-5

Characterization of cytotoxic CD4 T cells to promote cellular immunotherapy outcome in multiple myeloma
Hyunsoo Cho (Yonsei University College of Medicine, Korea)

YI-6

A study on the utility of next-generation sequencing-based assays for immunoglobulin gene rearrangement usage repertoire analysis and measurable residual disease monitoring in B-cell acute lymphoblastic leukemia
Daehyun Chu (University of Ulsan College of Medicine, Korea)

YI-7

Clinical impact of NGS-based measurable residual disease as prognostic marker in pediatric acute myeloid leukemia
Hyun Jin Park (Seoul National University College of Medicine, Korea)

DAILY PROGRAM Saturday, March 30

YI-8 Identification of relapse related clones using minimal residual disease monitoring by next-generation sequencing in Korean pediatric patients with acute myeloid leukemia

Jong-Mi Lee (College of Medicine, The Catholic University of Korea, Korea)

YI-9 The impact of the tumor immune microenvironment on the efficacy of CAR T-cell therapy or Bi-specific antibody therapy in relapsed or refractory diffuse large B-cell lymphoma

Hyungwoo Cho (University of Ulsan College of Medicine, Korea)

09:00-10:15

[ES06] Essential knowledge for optimal hematologic consultation (Kor)

Room 1
Vista Hall 1

Chairs

Jong Ho Won (Soonchunhyang University College of Medicine, Korea)

Deog-Yeon Jo (Chungnam National University College of Medicine, Korea)

ES06-1

Functional iron deficiency in cancer patients

Ik-Chan Song (Chungnam National University College of Medicine, Korea)

ES06-2

Assessment of neutropenia in hospitalized patients

Young Hoon Park (Ewha Womans University College of Medicine, Korea)

ES06-3

Perioperative consultation for the appropriate transfusion

Ka-Won Kang (Korea University College of Medicine, Korea)

09:00-10:15

[SS14] Novel insights into pathogenesis of MPN

Room 2
Vista Hall 2

Chairs

Chul Won Choi (Korea University College of Medicine, Korea)

Sung-Yong Kim (Konkuk University School of Medicine, Korea)

SS14-1

Myeloproliferative neoplasms and inflammation

Steffen Koschmieder (RWTH Aachen University, Germany)

SS14-2

Signaling contributing to the development of myelofibrosis: Beyond JAK/STAT

Douglas Tremblay (Mount Sinai School of Medicine, USA)

DAILY PROGRAM Saturday, March 30

SS14-3 **Clonal evolution in myelofibrosis**
Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea)

09:00-10:15 **[SS15] Immunotherapies for lymphomas non-benefited from CAR-T cell therapy** **Room 3**
Grand Hall 1

Chairs Jae-Yong Kwak (Jeonbuk National University Medical School, Korea)
Deok-Hwan Yang (Chonnam National University Medical School, Korea)

SS15-1 **Treatment options for relapsed/refractory Hodgkin lymphoma after brentuximab vedotin and PD-1 blockade**
Alex F. Herrera (City of Hope, USA)

SS15-2 **Aggressive B-cell lymphomas: Immuno-chemotherapies other than CAR-T cell therapies**
Jason Westin (The University of Texas MD Anderson Cancer Center, USA)

SS15-3 **Extranodal NK/T cell lymphoma: The immunogenic tumor**
Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)

09:00-10:15 **[ES07] Basic genomics for clinical hematologists (Kor)** **Room 4**
Art Hall

Chairs Hee-Jin Kim (Sungkyunkwan University School of Medicine, Korea)
In-Suk Kim (Pusan National University School of Medicine, Korea)

ES07-1 **Genomic technologies for detecting structural variations in hematologic malignancies**
Miae Jang (Sungkyunkwan University School of Medicine, Korea)

ES07-2 **The role of NGS in hematologic malignancies**
Young-Uk Cho (University of Ulsan College of Medicine, Korea)

ES07-3 **Germline predisposition to hematologic malignancies**
Sang Mee Hwang (Seoul National University College of Medicine, Korea)

10:15-10:30 **Break**

DAILY PROGRAM Saturday, March 30

10:30-11:15

[PAP01] Plenary Abstract Presentation

Room 1+2
Vista Hall 1+2

Chairs

Dong Yeop Shin (Seoul National University College of Medicine, Korea)
Yoon Seok Choi (Korea University College of Medicine, Korea)

PAP01-1

A single-arm, open-label, multicenter study to assess molecular response of P1101 therapy in patients with polycythemia vera and elevated hematocrit: Results from 48 weeks core study

Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea)

PAP01-2

Novel genomic variants influencing methotrexate delayed excretion in pediatric patients with acute lymphoblastic leukemia

Jung Yoon Choi (Seoul National University College of Medicine, Korea)

PAP01-3

Prognostic utility of minimal residual disease (MRD) after curative intent induction therapy for DLBCL: A prospective real-world ctDNA study

Sang Eun Yoon (Sungkyunkwan University School of Medicine, Korea)

11:15-11:45

Award Ceremony & Closing

Room 1+2
Vista Hall 1+2



iCKSH 2024

2024 KOREAN SOCIETY OF HEMATOLOGY
INTERNATIONAL CONFERENCE
& KSH 65th ANNUAL MEETING

POSTER LIST

POSTER LIST

- PP01-1 Genetic and epigenetic alteration of Wilms' tumor 1 (WT1) gene in acute myeloid leukemia**
Harsh Goel¹, Anita Chopra¹, Amar Ranjan¹, Jagdish Prasad Meena², Aditya Kumar Gupta², Ganesh Kumar Viswanathan³, Sameer Bakhshi⁴, Maroof Ahmad Khan⁵, Pranay Tanwar^{1*}

¹Laboratory Oncology, All India Institute of Medical Sciences, New Delhi, India

²Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India

³Hematology, All India Institute of Medical Sciences, New Delhi, India

⁴Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

⁵Biostatistics, All India Institute of Medical Sciences, New Delhi, India

- PP01-2 A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia**

Harsh Goel¹, Pranay Tanwar^{1*}

¹Laboratory Oncology, All India Institute of Medical Sciences, New Delhi, India

- PP01-3 Using red ginger to prevent acute myeloid leukemia : A literature review**

Farah Maetam^{1*}, Rahma Yuantari²

¹Internal Medicine, Universitas Islam Indonesia, Yogyakarta, Indonesia

²Clinical Pathology, Universitas Islam Indonesia, Yogyakarta, Indonesia

- PP01-4 Epigenetic modulation enhances the therapeutic potential of all-trans retinoic acid in acute myeloid leukemia**

Lukasz Szymanski^{1*}, Rafal Skopek¹, Malgorzata Palusinska¹, Karolina Maslinska-Gromadka¹, Leszek Kraj¹, Tino Schenk², Arthur Zelent¹

¹Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Magdalenka, Poland

²Institute of Molecular Cell Biology, Center for Molecular Biomedicine Jena (CMB), Jena University Hospital, Jena, Germany

- PP01-5 Loss of TET function results in myeloid malignancy associated with a heterochromatin-to-euchromatin transition**

Myunggon Ko^{1,2*}, Hiroshi Yuita³, Isaac Lopez-Moyado^{3,4}, Hyeonmin Jeong¹, James Scott-Browne⁵, Jungeun An⁶, Toshinori Nakayama^{7,8}, Atsushi Onodera^{3,7,9}, Anjana Rao^{3,4}

¹Biological Sciences, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea

²Center for Genomic Integrity, Institute for Basic Science, Ulsan, Republic of Korea

³Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, United States

⁴Sanford Consortium, For Regenerative Medicine, La Jolla, United States

⁵Biomedical Research, National Jewish Health, Denver, United States

⁶Life Sciences, Jeonbuk National University, Jeonju, Republic of Korea

⁷Immunology, Chiba University, Chiba, Japan

⁸AMED-CREST, AMED, Chiba, Japan

⁹Institute for Advanced Academic Research, Chiba University, Chiba, Japan

POSTER LIST

- PP01-6** High expression of CXC-chemokine ligand 5 in bone marrow serum predicts favorable outcomes in children with acute myeloid leukemia
Yongping Zhang¹, Hujun Li¹, Hui Zhang¹, Qi Ji¹, Li Gao¹, Yixin Hu¹, Shaoyan Hu^{1*}
¹Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China
- PP01-7** Gemtuzumab ozogamicin with half-dose CAG regimens as re-induction therapy for pediatric refractory/relapsed AML
Liyan Fan¹, Li Gao¹, Shengqin Cheng¹, Yixin Hu¹, Peifang Xiao¹, Hailong He¹, Yi Wang¹, Shaoyan Hu^{1*}
¹Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China
- PP01-8** Fabrication of revesterol hybrid lecithin folic acid silver nanoparticles and its evaluation as anti-leukemia effect against benzene induced acute myeloid leukemia in rats
Deeksha Chauhan^{1*}, Vikas Kumar²
¹Physics, RK College of Science, Uttarkhand, India
²Pharmaceutical Sciences, Sam Higginbottom University Of Agriculture, Technology & Sciences, Prayagraj, India
- PP01-9** CYP2B6 polymorphism and leukaemia susceptibility in Asian populations: A systematic review and meta-analysis
Novi Davitsen¹, Tohari Amin^{1*}, Alfateh Rahmi², Shinta Wardhani³
¹Internal Medicine Resident, Universitas Brawijaya, Malang, Indonesia
²Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
³Hemato-Oncology Divison of Internal Medicine Department, Universitas Brawijaya, Malang, Indonesia
- PP01-10** Treatment behavior and outcomes of acute myeloid leukemia in the COVID-19 era
Nayon Kim¹, Jeehyun Kong^{1*}
¹Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
- PP01-11** Exploring neo-antigen and immunogenicity of acute myeloid leukemia (AML) using neo-ARSTM artificial intelligence tool
Suyoung Choi^{1,2,3}, Joo-Young Kang⁴, Jeong Suk Koh⁵, Hyun-Jin Yang⁵, Jeong-Yeon Park⁵, Il-Oh Jeong⁶, Jong Hui Hong⁶, Jongsun Jung⁶, Thi Thuy Duong Pham^{1,2,3}, Bu-Yeon Heo^{1,2,3}, Myung-Won Lee⁴, Jung-Hyun Park⁷, Yunsun Jang⁷, Deog-Yeon Jo⁴, Jaeyul Kwon^{2,3,5,7,8}, Ik-Chan Song^{2,3,4}
¹Department of Infection Biology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
²Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
³Brain Korea 21 FOUR Project For Medical Science, Chungnam National University, Daejeon, Republic of Korea
⁴Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
⁵Genome Data Integration Centre, Syntekabio Inc., Daejeon, Republic of Korea
⁶Medical Science Study Centre, Syntekabio Inc., Seoul, Republic of Korea
⁷Translational Immunology Institute, College of Medicine, Chungnam National University, Seoul, Republic of Korea
⁸Department of Medical Education, College of Medicine, Chungnam National University, Daejeon, Republic of Korea

POSTER LIST

PP01-12 A paired sillico analysis of ALOX5AP gene expression/methylation and its prognostic impact among acute myeloid leukemia

Pranay Tanwar^{1*}, Harsh Goel¹

¹Laboratory Oncology, Dr BRA-IRCH, AIIMS, New Delhi, India

PP01-13 Investigation on novel ER transmembrane protein, SURF4, targeting cell death in myeloid leukemia

Jayoung Kim¹, Dongjun Lee^{1*}

¹School of Medicine, Convergence Medicine, Busan, Republic of Korea

PP01-14 Targeting estrogen-related receptor alpha as a novel treatment approach for acute myeloid leukemia with FLT3 mutation

Wonhyoung Seo¹, Ik-Chan Song², Eun-Kyeong Jo^{1*}

¹Department of Medical Science, Chungnam National University College of Medicine, Dajeon, Republic of Korea

²Department of Internal Medicine, Chungnam National University College of Medicine, Dajeon, Republic of Korea

PP01-15 Antithymocyte globulin (ATG) in allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: Evaluating outcomes according to cytogenetic risk: Impact on chronic GVHD and cGRFS

Hyeong Jun Kim¹, Mihee Kim², Seo-Yeon Ahn², Sung-Hoon Jung², Ga-Young Song², Deok-Hwan Yang², Je-Jung Lee², Mi Yeon Kim³, Hyeoung-Joon Kim^{2,3*}, Ho-Young Lim⁴, Jae-Sook Ahn^{2,3}

¹Internal Medicine, Chonnam National University Hospital, Gwang-ju, Republic of Korea

²Hematology, Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea

³Hematology, Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea

⁴Hematology, Hematology-Oncology, Jeonbuk National University Hospital, Jeonju, Republic of Korea

PP01-16 The oxysterols 27-hydroxycholesterol affects hematopoietic stem and progenitor cell pools

Soo-Yeon Woo

Department of Convergence Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea

PP01-17 From docking to overcoming resistance: Cannabidiol's potential in multidrug-resistant leukemia cancer K562/adr

Krai Daowtak

Medical Technology, Faculty of Allied Health Sciences, Cellular and Molecular Immunology Research Unit, Naresuan University, Phitsanulok, Thailand, Phitsanulok, Thailand

POSTER LIST

PP01-18

A real world analysis of impact of gilteritinib in relapse/refractory AML with FLT3-ITD mutation

Hohyung Nam^{1,2}, Daehun Kwag^{1,2}, Gi June Min^{1,2}, Sung-Soo Park^{1,2}, Silvia Park^{1,2}, Jae-Ho Yoon^{1,2}, Sung-Eun Lee^{1,2}, Byung Sik Cho^{1,2*}, Ki-Seong Eom^{1,2}, Yoo-Jin Kim^{1,2}, Seok Lee^{1,2}, Chang-Ki Min^{1,2}, Seok -Goo Cho¹, Jong Wook Lee¹, Hee-Je Kim^{1,2}

¹Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Republic of Korea

PP01-19

Enhanced expression of glycolytic enzymes and succinate dehydrogenase complex flavo-protein subunit a by HMP promotes glycolysis and mitochondrial respiration in myeloblasts of acute myeloid leukemia

Yunseon Jang¹, Jeong Suk Koh², Jung-Hyun Park¹, Suyoung Choi^{3,4}, Pham Thi Thuy Duong^{3,4}, Bu Yeon Heo^{3,4}, Sang Woo Lee⁴, Jung Yeon Kim⁵, Seok-Hwan Kim^{5,6}, Ik-Chan Song^{1,2*}

¹Translational Immunology Institute, Chungnam National University School of Medicine, Daejeon, Republic of Korea

²Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea

³Brain Korea 21 FOUR Project for Medical Science, Chungnam National University School of Medicine, Daejeon, Republic of Korea

⁴Department of Medical Science, Chungnam National University School of Medicine, Daejeon, Republic of Korea

⁵Research Institute for Medical Science, Chungnam National University School of Medicine, Daejeon, Republic of Korea

⁶Department of Surgery, Chungnam National University Hospital, Daejeon, Republic of Korea

PP01-20

Risk stratification in AML through early bone marrow assessment during intensive chemotherapy

Daehun Kwag^{1,2}, Gi June Min^{1,2}, Sung-Soo Park^{1,2}, Silvia Park^{1,2}, Jae-Ho Yoon^{1,2}, Sung-Eun Lee^{1,2}, Byung Sik Cho^{1,2}, Ki-Seong Eom^{1,2}, Yoo-Jin Kim^{1,2}, Seok Lee^{1,2}, Chang-Ki Min^{1,2}, Seok -Goo Cho¹, Chang-Ki Min^{1,2}, Jong Wook Lee¹, Hee-Je Kim^{1,2*}

¹Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

PP01-21

Genomic landscape of pediatric acute myeloid leukemia (AML)

Jagdish Prasad Meena^{1*}, Riyaz Ahmad Mir¹, Harshita Makkar¹, Aditya Kumar Gupta¹, Sameer Bakhshi¹, Rakhee Yadav¹, Pranay Tanwar¹, Rachna Seth¹

¹Division of Pediatric Oncology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India, New Delhi, India

POSTER LIST

PP01-22 An artificial intelligence approach for measurable residual disease (MRD) detection in acute myeloid leukemia (AML)

Pranay Tanwar^{1*}, Jaspreet Singh², Harsh Goel¹

¹Laboratory Oncology Unit, Dr.B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

²Laboratory Oncology Unit, ICMR-National Institute of Pathology, Sriramachari Bhawan, Safdarjung Hospital Campus, New Delhi, India

PP01-23 Glutathione S-transferases (GST) T1 polymorphism as the most susceptible to leukemia in Asians population: An updated meta-analysis and systematic review of multicenter study

Tohari Tohari^{1*}, Muhammad Saifulhaq¹, Anindia Yolanda², Alfatea Rahmi³, Shinta Wardhani⁴

¹Internal Medicine Resident, Universitas Brawijaya, Malang, Indonesia

²Emergency Department, Lavalette Hospital, Malang, Indonesia

³Medical student, Universitas Brawijaya, Malang, Indonesia

⁴Hematology Oncology Division of Internal Medicine Department, Universitas Brawijaya, Malang, Indonesia

PP01-24 GSTP1 val allele is associated with susceptibility to acute myeloid leukemia: A meta-analysis

Raphael Enrique Tiongco¹, Neil David Cayan¹, Miljun Catacata^{1*}, Michael John Dominguez²

¹College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines

²School of Medicine, Angeles University Foundation, Angeles City, Philippines

PP01-25 Impaired CD45RO-CCR7+ naive CD8+T cells in AML are associated with lower overall survival

Yongping Zhang¹, Hujun Li¹, Hui Zhang¹, Qi Ji¹, Shaoyan Hu^{1*}

¹Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China

PP01-26 Dysregulation of immune regulators in AML bone marrow promotes dysfunction of CD8+ T cells

Yongping Zhang¹, Hujun Li¹, Hui Zhang¹, Qi Ji¹, Shaoyan Hu^{1*}

¹Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China

PP01-27 Acute promyelocytic leukemia with abundant small azurophilic granules: A case report

Yeon Woo Seo¹, Sang Kyung Kim^{1*}

¹Laboratory Medicine, Daegu Catholic University School of Medicine, Daegu, Republic of Korea

POSTER LIST

PP01-28

Exploring genomic complexity in acute myeloid leukemia through machine learning: Subtype identification, biomarker discovery, and prognostic models for personalized interventions

Rifaldy Fajar^{1*}, Laura Barbara², Alessio Conta Rossi^{3,2}, Sofia Clara Binico^{3,2}, Erik Santa Andersson⁴, Roland Helmizar⁵

¹Information Engineering, Computer Science and Mathematics, University of L'Aquila, L'Aquila, Italy

²Computational Biology and Medicine Laboratory, University of L'Aquila, L'Aquila, Italy

³Hematology Research Unit, L'Aquila Hospital, L'Aquila, Italy

⁴Bioinformatics Research Group, Karlstad University, Karlstad, Sweden

⁵Internal Medicine, Baiturrahmah University, Padang, Indonesia

PP01-29

The role of allogeneic stem cell transplantation in the aml patients who were treated with venetoclax and decitabine

Ik Chan Song¹, Jeong Suk Koh¹, Wonhyoung Seo¹, Sora Kang¹, Chul Hee Kim¹, Myung-Won Lee¹, Hyewon Ryu¹, Hyo-Jin Lee¹, Hwan-Jung Yun¹, Deog-Yeon Jo^{1*}

¹Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea

PP01-30

Comparison of the current and 2022 system of the WHO classification of non-recurrent genetic abnormalities acute myeloid leukemia in the real-world setting

Hye Seong Ryu¹, Young-Uk Cho^{1*}, Daehyun Chu¹, Taeguen Lee¹, Miyoung Kim¹, Seongsoo Jang¹

¹Laboratory Medicine, Asan Medical Center, Seoul, Republic of Korea

PP01-31

Risk factors and infection patterns of febrile neutropenia after induction chemotherapy in patients with acute myeloid leukemia

Made Sindy Astri Pratiwi¹, Made Priska Arya Agustini¹, Ni Made Renny Anggreni Rena^{2*}, I Made Bakta²

¹Faculty of Medicine, Udayana University/ Prof. dr. I.G.N.G Ngoerah General Hospital, Denpasar, Bali, Indonesia

²Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Udayana University/ Prof. dr. I.G.N.G Ngoerah General Hospital, Denpasar, Bali, Indonesia

PP01-32

Survival analysis of acute myeloid leukemia patients at tertiary care hospital in Bali, Indonesia

Made Priska Arya Agustini¹, Made Sindy Astri Pratiwi¹, Ni Made Renny Anggreni Rena^{2*}, I Made Bakta²

¹Faculty of Medicine, Premagana General Hospital, Gianyar, Denpasar, Bali, Indonesia

²Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Udayana University, Bali, Indonesia, Faculty of Medicine, Udayana University, Bali, Indonesia, Denpasar, Bali, Indonesia

POSTER LIST

PP01-33 The efficacy of midostaurin in patients with FLT3-ITD mutated AML : A real-world setting in Korea

Kyoung Il Min^{1,2}, Daehun Kwag^{1,2}, Jung Yeon Lee^{1,2}, Gi June Min^{1,2}, Sung-Soo Park^{1,2}, Silvia Park^{1,2}, Jae-Ho Yoon^{1,2}, Sung-Eun Lee^{1,2}, Byung Sik Cho^{1,2}, Ki-Seong Eom^{1,2}, Yoo-Jin Kim^{1,2}, Seok Lee^{1,2}, Chang-Ki Min^{1,2}, Seok -Goo Cho¹, Jong Wook Lee¹, Hee-Je Kim^{1,2*}

¹Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

PP01-34 Hypomethylating agent plus venetoclax treatment outcome in core binding factor acute myeloid leukemia

Daehun Kwag^{1,2}, Gi June Min^{1,2}, Sung-Soo Park^{1,2}, Silvia Park^{1,2}, Jae-Ho Yoon^{1,2}, Sung-Eun Lee^{1,2}, Byung Sik Cho^{1,2}, Ki-Seong Eom^{1,2}, Yoo-Jin Kim^{1,2}, Seok Lee^{1,2}, Chang-Ki Min^{1,2}, Seok -Goo Cho¹, Jong Wook Lee¹, Hee-Je Kim^{1,2*}

¹Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

PP01-35 Gamma delta T-cell immune checkpoint receptor expression in acute myeloid leukemia

Daehun Kwag^{1,2}, Byung Sik Cho^{1,2*}, Gi June Min^{1,2}, Sung-Soo Park^{1,2}, Silvia Park^{1,2}, Jae-Ho Yoon^{1,2}, Sung-Eun Lee^{1,2}, Ki-Seong Eom^{1,2}, Yoo-Jin Kim^{1,2}, Seok Lee^{1,2}, Chang-Ki Min^{1,2}, Seok-Goo Cho¹, Jong Wook Lee¹, Hee-Je Kim^{1,2}

¹Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

PP01-36 In vitro long-term culture conditions screening for primary AML sample

Daehyeon Gwak^{1,2}, Dongchan Kim^{1,2}, Ja Min Byun^{1,2,3}, Junshik Hong^{1,2,3}, Sung-Soo Yoon^{1,2,3}, Dong-Yeop Shin^{1,2,3*}

¹Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

²Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea

³Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

POSTER LIST

PP02-1

Impact of transfusion dependence on clinical and economic burden in patients with low-risk myelodysplastic syndromes: A 28-year retrospective study

Jun Ho Jang^{1*}, Ji-Hyun Kim², Kyungah Lee³, Hyojin Kim⁴, Fangyuan Wang⁵

¹Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

²Medical Affairs, Bristol Myers Squibb Korea, Seoul, Republic of Korea

³Market Access, Bristol Myers Squibb Korea, Seoul, Republic of Korea

⁴RWE, Syneos Health Korea, Seoul, Republic of Korea

⁵Data Analytics RWE, Syneos Health China, Beijing, China

PP02-2

Unlocking myelodysplastic syndrome insights: Meta-analysis and machine learning with MUHSeq tool for blood transcriptome analysis

Mohammad Uzzal Hossain

Bioinformatics Division, National Institute of Biotechnology, Dhaka, Bangladesh

PP02-3

Potential biomarkers for azacitidine resistance in myelodysplastic syndrome based on gene expression and DNA methylation profiles

Da Yeon Kim^{1,2}, Eun Ju Kim^{1,2,3,4*}

¹Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea

²Department of Radiological and Medico-Oncological Sciences, University of Science and Technology, Daejeon, Republic of Korea

³Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia

⁴Genomics and Machine Learning Lab, QIMR Berghofer Medical Research Institute, Brisbane, Australia

PP02-4

Chromosomal abnormalities in primary myelodysplastic syndrome

Anila Rashid^{1*}, Mohammad Khurshid¹

¹Haematology, Aga Khan University Hospital, Karachi, Pakistan

PP02-5

Subtype-specific germline DDX41 mutations and their distinct clinicopathological features in Korean patients with myelodysplastic syndrome and acute myeloid leukemia

Daehyun Chu¹, Young-Uk Cho^{1*}, Taegeun Lee¹, Miyoung Kim¹, Sang-Hyun Hwang¹, Seongsoo Jang¹, Eul-Ju Seo¹

¹Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

POSTER LIST

- PP02-6** **Trafficking of NK-cells into bone marrow after hypomethylating agent treatment in mice and patients with high risk MDS or AML**
Junshik Hong^{1,2*}, Suji Min¹, Jihyun Park¹, Carly Fielder³, Qianni Hu³, Sung-Soo Yoon^{1,2}, Tae Kon Kim³
¹Hematology Laboratory, Seoul National University Hospital, Seoul, Republic of Korea
²Department of Internal Medicine, Seoul National University College of Medicine, Nashville, Republic of Korea
³Division of Hematology-Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, United States
- PP02-7** **Reclassification of myelodysplastic neoplasms following updated WHO and ICC classification: A single center study**
A-Jin Lee^{1*}, Sang-Gyung Kim¹, Sung Hwa Bae²
¹Department of Laboratory Medicine, Daegu Catholic University Medical Center, Daegu, Republic of Korea
²Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Republic of Korea
- PP03-1** **Efficacy and 5 years survival of acute lymphoblastic leukemia (ALL) treated with bacterial L-asparaginase**
Natya Lakshita Ardhananeswari Riyanto
Faculty of Medicine, Universitas Islam Indonesia, Yogyakarta, Indonesia
- PP03-2** **A pancytopenia preceeding a hypoplastic acute lymphoblastic leukemia**
Daniela Ratnani^{1*}, Lusi Oka Wardhani¹
¹Department of Clinical Pathology, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia
- PP03-3** **The association between GSTM1 and GSTT1 null genotype and susceptibility to leukemia in Asian population: A systematic review and meta-analysis**
Salsabila Farradisya¹, Alfatea Pintari Rahmi^{1*}, Evira Rahma Aya Sofia¹, Tohari Tohari², Shinta Oktya Wardhani³
¹Medical Faculty, Universitas Brawijaya, Malang, Indonesia
²Internal Medicine Department, Universitas Brawijaya, Malang, Indonesia
³Hemato-Oncology Division of Internal Medicine Department, Universitas Brawijaya, Malang, Indonesia
- PP03-4** **IKZF1 deletion status and correlation with cytogenetics and measurable residual disease in adult B lineage acute lymphoblastic leukemia**
Prabhjot Kaur¹, Sudhanshi Raina¹, Anand Balakrishnan¹, Anshu Anshu¹, Shailja Rathore¹, Pramod Kumar¹, Parveen Bose¹, Jogeshwar Binota¹, Praveen Sharma¹, Shano Naseem¹, Arihant Jain¹, Alka Khadwal¹, Man Updesh Singh Sachdeva¹, Reena Das¹, Sreejesh Sreedharanunni^{1*}
¹Hematology, Post-Graduate Institute of Medical Education & Research, Chandigarh, India

POSTER LIST

- PP03-5** **5-Methyl cytosine flow cytometry-based global methylation status and correlation with cytogenetics and measurable residual disease in adult B lineage acute lymphoblastic leukemia**
Prabhjot Kaur¹, Sudhanshi Raina¹, Arun Kumar¹, Parveen Bose¹, Jogeshwar Binota¹, Shano Naseem¹, Arihant Jain¹, Alka Khadwal¹, Man Updesh Singh Sachdeva¹, Sreejesh Sreedharanunni^{1*}
¹Hematology, Post-Graduate Institute of Medical Education & Research, Chandigarh, India
- PP03-6** **Clinical impact of concurrent BTG anti-proliferation factor 1 (BTG1) and IKZF1 deletions in BCR::ABL1 negative B-cell acute lymphoblastic leukemia**
Sanjeev Kumar Gupta^{1*}, Gadha K Leons¹, Preity Sharma¹, Sameer Bakhshi², Ritu Gupta¹, Smeeta Gajendra¹, Deepam Pushpam²
¹Laboratory Oncology, AIIMS, New Delhi, Delhi, India
²Medical Oncology, AIIMS, New Delhi, Delhi, India
- PP03-7** **Prognostic analysis of WT1 expression at diagnosis in pediatric acute lymphoblastic leukemia: A retrospective study from Seoul National University Children's Hospital**
Bo Kyung Kim¹, Hyun Jin Park¹, Jung Yoon Choi¹, Kyung Taek Hong¹, Juyeon Lee¹, Youngdai Kwon¹, Yoon Sunwoo¹, Hyoung Jin Kang^{1*}
¹Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea
- PP03-8** **Key role of SOX4 and PI3K/AKT/mTOR pathway in relapsed pediatric precursor B cell acute lymphoblastic leukemia**
Jae Wook Lee^{1*}, Suejung Jo¹, Jae Won Yoo¹, Seongkoo Kim¹, Nack-Gyun Chung¹, Bin Cho¹
¹Division of Pediatric Hematology/Oncology, Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
- PP03-9** **Second hematologic malignancy risk following radioactive iodine therapy in thyroid cancer patients: A systematic review and meta-analysis**
Evira Rahma Aya Sofia^{1*}, Alfatea Pintari Rahmi¹, Salsabila Farradisya¹, Tohari Tohari², Shinta Oktya Wardhani³
¹Medical Faculty, Universitas Brawijaya, Malang, Indonesia
²Department of Internal Medicine, Universitas Brawijaya, Malang, Indonesia
³Hemato-Oncology Division of Internal Medicine Department, Universitas Brawijaya, Malang, Indonesia

POSTER LIST

PP03-10

Bioinformatics analysis of genomic alterations in pediatric acute lymphoblastic leukemia: Identifying prognostic markers and therapeutic targets

Rifaldy Fajar^{1*}, Bona Francesco^{2,3}, Celeste Bonita Santana³, Victor Zheyn⁴, Betty Nakyama Bad-deh^{1,4}, Claudia Mendosa^{2,3}, Andi Nursanti Andi Ureng⁵

¹Information Engineering, Computer Science and Mathematics, University of L'Aquila, L'Aquila, Italy

²Cancer Genomics Laboratory, University of L'Aquila, L'Aquila, Italy

³Pediatric Hematology-Oncology Department, L'Aquila Hospital, L'Aquila, Italy

⁴Computational Biology and Medicine Laboratory, University of L'Aquila, L'Aquila, Italy

⁵Pharmacy, Andini Persada College of Health Sciences, Mamuju, Indonesia

PP03-11

Clinical implication of ponatinib salvage in adult patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Jae-Ho Yoon¹, Daehun Kwag¹, Gi June Min¹, Sung-Soo Park¹, Silvia Park¹, Sung-Eun Lee¹, Byung-Sik Cho¹, Ki-Seong Eom¹, Yoo-Jin Kim¹, Hee-Je Kim¹, Chang-Ki Min¹, Seok-Goo Cho¹, Jong Wook Lee¹, Seok Lee^{1*}

¹Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

PP03-12

Minimal residual disease-based effect and safety of frontline ponatinib plus hyper-CVAD treatment for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Seunghan Kim¹, Jae-Ho Yoon^{1*}, Daehun Kwag¹, Gi June Min¹, Sung-Soo Park¹, Silvia Park¹, Sung-Eun Lee¹, Byung-Sik Cho¹, Ki-Seong Eom¹, Yoo-Jin Kim¹, Hee-Je Kim¹, Chang-Ki Min¹, Seok-Goo Cho¹, Jong Wook Lee¹, Seok Lee¹

¹Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

PP03-13

The potential of extracellular vesicle derived microRNAs as a biomarker in acute lymphoblastic leukemia

Jeong-An Gim², Kunye Kwak¹, Yong Park¹, Byung Soo Kim¹, Ka-Won Kang^{1*}

¹Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea

²Department of Medical Science, Soonchunhyang University, Asan, Republic of Korea

PP03-14

An updated meta-analysis of the association of IKAROS zinc finger 1 rs4132601 T>G gene polymorphism with acute lymphoblastic leukemia risk

Batara Bisuk^{1*}, William Djauhari², Shania Sondang Ni Bulan³

¹Internal Medicine, Weda General Hospital, Weda, Indonesia

²Internal Medicine, Eka Hospital BSD, BSD, Indonesia

³Internal Medicine, Sipirok General Hospital, Sipirok, Indonesia

POSTER LIST

PP04-1

Aberrant DNA methylation of tumor suppressor gene as one possible mechanism of its under-expression in chronic myeloid leukemia patients in India

Asgar Ali¹, Sadhana Sharma^{1*}

¹Biochemistry, All India Institute of Medical Sciences, Patna, India

PP04-2

Biological potential and therapeutic effectiveness of Hinokiflavone for the treatment of chronic myeloid leukemia with their molecular mechanisms

Dinesh Kumar Patel^{1*}, Kanika Patel¹

¹Faculty of Health Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, India

PP04-3

Methylenetetrahydrofolate reductase A1298C gene polymorphism with risk of chronic myeloid leukemia: Updated meta-analysis

William Djauhari¹, Bataras Bisuk²

¹Diabetes Connection Care, Eka Hospital BSD, Tangerang Selatan, Indonesia

²Internal Medicine, Weda General Hospital, Weda, Indonesia

PP04-4

Improvement of treatment-free remission rate following discontinuation of BCR::ABL1 tyrosine kinase inhibitors with longer treatment duration in chronic myeloid leukemia

Sewon Lee¹, Yeung-Chul Mun¹, Hongtae Kim², Semin Lee³, Seunghoon Kim³, Sung-Ho Park², Sung-Hyun Kim⁴, Young Rok Do⁵, Soo-Hyun Kim⁶, Kyung-Mi Kee⁶, Yoon Sung Lee⁷, Dong-Wook Kim^{6,8*}

¹Hematology and Oncology, Ewha Womans University Mokdong Hospital, Seoul, Republic of Korea

²Biological Science, Ulsan National Institute of Science & Technology, Ulsan, Republic of Korea

³Biomedical Engineering, College of Information-Bio Convergence Engineering Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea

⁴Hematology and Oncology, Dong-A University Medical Center, Busan, Republic of Korea

⁵Hematology and Oncology, Dongsan Medical Center, Keimyung University, Daegu, Republic of Korea

⁶Leukemia Omics Research Institute, Eulji University, Uijeongbu, Republic of Korea

⁷Biological Science, Kyunghee University Hospital, Seoul, Republic of Korea

⁸Hematology, Eulji Medical Center, Seoul, Republic of Korea

PP04-5

Association between waist circumference, body mass index, high-density lipoprotein cholesterol level, and risk of chronic myeloid leukemia

Ka Young Kim¹, Daehun Kwag¹, Jung Yeon Lee¹, Gi-June Min¹, Sung-Soo Park¹, Silvia Park¹, Jae-Ho Yoon¹, Byung-Sik Cho¹, Ki-Seong Eom¹, Yoo-Jin Kim¹, Seok Lee¹, Chang-Ki Min¹, Hee-Je Kim¹, Seok-Goo Cho¹, Jong Wook Lee¹, Kyung Do Han², Sung-Eun Lee^{1*}

¹Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea

POSTER LIST

PP04-6

Enumeration of CD26+ leukemic stem cells from peripheral blood using multiparametric flow cytometry: A potential tool for rapid diagnosis of chronic myeloid leukemia

Praveen Sharma^{1*}, Namrata Kaul¹, Man Updesh Singh Sachdeva¹, Shano Naseem¹, Anshul Sabharwal¹, Sreejesh Sreedharanunni¹, Parveen Bose¹, Arun Kumar¹, Bhavishan Thakur¹, Pankaj Malhotra²

¹Hematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, Chandigarh, India

²Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, Chandigarh, India

PP04-7

A successful leukapheresis in the management of chronic myeloid leukemia (CML) patients with pulmonary leukostasis: A case report and review of the literature

Tohari Tohari¹, Alfatea Rahmi^{2*}, Shinta Wardhani³

¹Internal Medicine Resident, Universitas Brawijaya, Malang, Indonesia

²Medical student, Universitas Brawijaya, Malang, Indonesia

³Hemato-Oncology Division of Internal Medicine Department, Universitas Brawijaya, Malang, Indonesia

PP04-8

The role of the microbiome gut axis in the development and relapse of chronic myeloid leukemia: Systematic review

Daivan Febri Juan Setiya^{1*}, Dinda Ashilah Putri Kusnan², Ety Sari Handayani³

¹Medical Student, Faculty of Medicine, Islamic University of Indonesia, Islamic University of Indonesia, Sleman, Indonesia

²Medical Student, Faculty of Medicine, Islamic University of Indonesia, Gadjah Mada University, Sleman, Indonesia

³Department of Anatomy, Islamic University of Indonesia, Sleman, Indonesia

PP04-9

Impact of first-line and second-generation tyrosine kinase inhibitors on quality of life in chronic myeloid leukemia: Insights from a multi-center prospective study

Sahnaz Vivinda Putri^{1*}, Elfiany Elfiany², Budi Karunia³, Andi Nursanti Andi Ureng⁴

¹Health Management Laboratory, International University Semen Indonesia, Gresik, Indonesia

²Computational Science Research Laboratory, Bulukumba Muhammadiyah University, Bulukumba, Indonesia

³Hematology Research Unit, Takalar General Hospital, Takalar, Indonesia

⁴Pharmacy, Andini Persada College of Health Sciences, Mamuju, Indonesia

PP04-10

Paclitaxel and curcumin as dual-drug-loaded lipid nanocapsules exhibited protective effect against chronic myeloid leukemia via promotes apoptosis and suppress the BCR/ABL

Vikash Kumar^{1*}, Mahfoozur Rahman¹

¹Natural product, Natural Product Drug Discovery Laboratory, PRJN, India

POSTER LIST

PP04-11

Predictive factors of patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitor

Ni Made Renny Anggreni Rena^{1*}, Ketut Suega¹, I Made Bakta¹

¹Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Udayana University, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia

PP04-12

Low level mutations in the BCR-ABL1 kinase domain confers resistance to tyrosine kinase inhibitor in chronic myeloid leukemia patients

Mohd Fadly Md Ahid^{1*}, Zahidah Abu Seman², Yuslina Mat Yusoff², Siti Shahrum Muhamed Said³, Norazlina Azman³, Julia Abdullah², Ermi Neiza Mohd Sahid², Nor Rizan Kamaluddin², Ezalia Esa²

¹Centre for Medical Laboratory Technology Studies, Faculty of Health Sciences, Universiti Teknologi MARA, Puncak Alam, Malaysia

²Hematology Unit, Cancer Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Malaysia

³Department of Pathology, Hospital Tunku Azizah, Ministry of Health Malaysia, Kuala Lumpur, Malaysia

PP05-1

In silico electrophysiological study reveals ibrutinib, an important therapeutic agent for B-cell lymphoma causes cardiac toxicity by inhibiting sodium current

Chitaranian Mahapatra^{1*}, Kaustav Das²

¹Biotherapy & Oncology, Paris Saclay University, Saclay, France

²Bio Sciences, Indian Institute of Sciences, Bangalore, India

PP05-2

Subcutaneous epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma from EPCORE NHL-5

Won Seog Kim^{1*}, Irit Avivi², Po-Shen Ko³, Carlos Grande Garcia⁴, David Lavie⁵, David Chism⁶, Mostafa Seliem⁷, Edwin E. Jeng⁷, Neha Joshi⁸, Satya Siddani⁹, Wissam Assaily¹⁰, Mariana Sacchi¹¹, Minh Dinh⁷, Abraham Avigdor¹²

¹Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea

²Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

³Division of Hematology, Taipei Veterans General Hospital Division of Hematology, Taipei City, Taiwan

⁴Department of Hematology, Clinica Universidad de Navarra, Madrid, Spain

⁵Department of Hematology, Hadassah Medical Center, Jerusalem, Israel

⁶Oncology, Thompson Cancer Survival Center, Knoxville, United States

⁷Oncology Clinical Development, AbbVie, North Chicago, United States

⁸Data and Statistical Sciences, AbbVie, North Chicago, United States

⁹Statistical Sciences and Analytics, AbbVie, North Chicago, United States

¹⁰Precision Medicine, AbbVie, North Chicago, United States

¹¹Clinical Research, Genmab, Plainsboro, United States

¹²Division of Hematology and BMT, Sheba Medical Center, Ramat Gan and Tel Aviv University, Tel Aviv, Israel

POSTER LIST

PP05-3

The clinical impact of PDGFR expression in patients with relapsed/refractory non-Hodgkin lymphoma treated with imatinib-combined chemotherapy: A pilot study

Seom Gim Kong¹, Min-Jung Kim², Daejin Park³, Hee Kyung Jang⁴, Su-Jin Heo⁵, Da Jung Kim⁶, Jae-Cheol Jo⁷, Jee-Yeong Jeong^{2,8}, Ho Sup Lee^{6*}

¹Department of Pediatrics, Kosin University College of Medicine, Busan, Republic of Korea

²Department of Biochemistry, Kosin University College of Medicine, Busan, Republic of Korea

³Doremi Clinic, 298, Suyeong-ro, Nam-gu, Busan, Republic of Korea

⁴Department of Pathology, Kosin University College of Medicine, Busan, Republic of Korea

⁵Central Medical Research Institute, Kosin University Gospel Hospital, Busan, Republic of Korea

⁶Department of Internal Medicine, Kosin University College of Medicine, Busan, Republic of Korea

⁷Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea

⁸Institute for Medical Science, Kosin University College of Medicine, Busan, Republic of Korea

PP05-4

Matching-adjusted indirect treatment comparison of axicabtagene ciloleucel and historical treatments in high-risk large B-cell lymphoma using Samsung Medical Center lymphoma registry

Yeeun Choi¹, Sungho Bea¹, Ju Hwan Kim¹, Sang Eun Yoon², Won Seog Kim^{2,3}, Seok Jin Kim^{2,3*}, Ju-Young Shin^{1,4,5}

¹School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea

²Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea

³Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea

⁴Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Republic of Korea

⁵Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea

PP05-5

The role of small bowel video capsule endoscopy in determining the treatment strategy for duodenal follicular lymphoma

Gi June Min¹, Donghoon Kang², Tong Yoon Kim³, Young-Woo Jeon³, Yukyung Cho², Jae Myung Park², Joo Hyun O⁴, Byung-Ock Choi⁵, Gyeong-Sin Park⁶, Seok-Goo Cho^{1*}

¹Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

²Gastroenterology and Hepatology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

³Hematology, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

⁴Nuclear Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

⁵Radiation Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

⁶Hospital Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

POSTER LIST

PPOS-6

Mitigating cytokine release syndrome (CRS) in diffuse large B-cell lymphoma (DLBCL) with cycle 1 optimization: Preliminary results from EPCORE NHL-1

Won Seog Kim^{1*}, Julie M. Vose², Tatyana Feldman³, Martine E.d. Chamuleau⁴, Pieterella Lugtenburg⁵, Pau Abrisqueta⁶, Chan Y. Cheah⁷, Ingrid Glimelius⁸, Brian Hess⁹, Wojciech Jurczak¹⁰, Gerardo Musuraca¹¹, Adam J. Olszewski¹², Minh Dinh¹³, Nurgul Kilavuz¹⁴, Monica Wielgos-Bonvallet¹⁴, Tommy Li¹⁴, Zhu Li¹⁴, Christian Eskelund¹⁵, Umar Farooq¹⁶, Tae Min Kim¹⁷

¹Hematology and Oncology, Samsung Medical Center, Seoul, Republic of Korea

²Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, United States

³Lymphoma & Hematology, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack Meridian Health School of Medicine, Hackensack, United States

⁴Hematology, On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands

⁵Department of Hematology, On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands

⁶Haematology and Haemotherapy, Hospital Universitario Vall d'Hebron, Barcelona, Spain

⁷Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia

⁸Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden

⁹Hematology/Oncology, Medical University of South Carolina, Charleston, United States

¹⁰Department of Clinical Oncology, MSC National Research Institute of Oncology, Krakow, Poland

¹¹Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy

¹²Hematology and Oncology, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, United States

¹³Oncology, AbbVie, North Chicago, United States

¹⁴Oncology, Genmab, Plainsboro, United States

¹⁵Department of Haematology, Genmab, Copenhagen, Denmark

¹⁶Lymphoma, University of Iowa, Iowa City, United States

¹⁷Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

PPOS-7

Physician-reported treatment patterns and outcomes in marginal zone lymphoma in South Korea

Seok Jin Kim^{1*}, Seug Yun Yoon², Sharon Chua³, Hyeran Byun⁴, Jiyeon Kim⁴, Junice Ng⁵

¹Department of Hematology and Oncology, Samsung Medical Center, Seoul, Republic of Korea

²Department of Hematology and Oncology, Soon Chun Hyang University Hospital, Seoul, Republic of Korea

³Real World Solutions, IQVIA Asia Pacific, Singapore, Singapore

⁴Medical Affairs, BeiGene South Korea, Seoul, Republic of Korea

⁵Health Economics and Outcomes Research, BeiGene Global, Singapore, Singapore

POSTER LIST

PP05-8

The long-term impact of rituximab-based chemoimmunotherapy in patients with DLBCL, real world outcomes using national health insurance database of South Korea

Hyun Jung Lee¹, Dong Wook Kim³, Jae Joon Han¹, Myung Hee Chang^{2*}

¹Internal Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea

²Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea

³Information and Statistics, Gyeongsang National University, Republic of Korea

PP05-9

Outcomes in refractory diffuse large B-cell lymphoma: Results from subgroup analysis of two prospective Korean cohort studies

Jun Ho Yi¹, Seong Hyun Jeong², Seok Jin Kim³, Dok Hyun Yoon⁴, Hye Jin Kang⁵, Youngil Koh⁶, Jin Seok Kim⁷, Won-Sik Lee⁸, Deok-Hwan Yang⁹, Young Rok Do¹⁰, Min Kyoung Kim¹¹, Hyeon-Seok Eom¹², Kwai Han Yoo¹³, Jae-Yong Kwak¹⁴, Jae-Cheol Jo¹⁵, Ho-Jin Shin¹⁶, Ho-Sup Lee¹⁷, Sung Yong Oh¹⁸, Byeong Bae Park¹⁹, Won Seog Kim^{3*}

¹Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Republic of Korea

²Department of Internal Medicine, Ajou University School of Medicine, Suwon, Republic of Korea

³Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

⁴Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

⁵Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Republic of Korea

⁶Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

⁷Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

⁸Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Republic of Korea

⁹Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea

¹⁰Department of Internal Medicine, Dongsan Medical Center, Daegu, Republic of Korea

¹¹Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea

¹²Department of Internal Medicine, National Cancer Center, Goyang, Republic of Korea

¹³Department of Internal Medicine, Gachon University College of Medicine, Incheon, Republic of Korea

¹⁴Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Republic of Korea

¹⁵Department of Internal Medicine, Ulsan University Hospital, Ulsan, Republic of Korea

¹⁶Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea

¹⁷Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea

¹⁸Department of Internal Medicine, Dong-A University Medical Center, Busan, Republic of Korea

¹⁹Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea

POSTER LIST

PP05-10

Trial in progress: A global phase 2 basket trial of nanatinostat in combination with valganciclovir in patients with EBV-positive (EBV+) relapsed/refractory lymphomas (NAVAL-1)

Young-Rok Do^{1*}, Won Sik Lee², Jae Hoon Lee³, Dong Won Baek⁴, Seok-Goo Cho⁵, Donald Strickland⁶, Won Seog Kim⁷

¹Division of Hemato-Oncology, Keimyung University Dongsan Hospital, Daegu, Republic of Korea

²Department of Internal Medicine, Hemato-Oncology, Inje University Haeundae Paik Hospital, Busan, Republic of Korea

³Department of Hemato-oncology, Gachon University Gil Medical Center, Incheon, Republic of Korea

⁴Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Republic of Korea

⁵Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

⁶Medical, Viracta Therapeutics, Inc., Cardiff, CA, United States

⁷Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea

PP05-11

Time to next treatment in patients with pre-treated cutaneous T-cell lymphoma receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis

Youn Hee Kim¹, Pablo Ortiz-Romero², Barbara Pro³, Lubomir Sokol⁴, Julia Scarisbrick⁵, Amy Musiek⁶, Maarten Vermeer⁷, Reinhard Dummer⁸, Ahmad Halwani⁹, Maria Fierro¹⁰, Junji Moriya¹¹, Ki Hyon Kim^{12*}, Jungah Hwang¹³, Martine Bagot¹⁴

¹Department of Dermatology, Stanford University School of Medicine, Stanford, United States

²Dermatologia, Instituto 12, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain

³Department of Oncology, Northwestern University, Evanston, United States

⁴Department of Hematology/Oncology, H. Lee Moffitt Cancer Center, Tampa, United States

⁵Lymphoma Service, University Hospitals Birmingham, Birmingham, United Kingdom

⁶Department of Dermatology, Washington University, St Louis, United States

⁷Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands

⁸Department of Dermatology, Universitatsspital Zurich, Zurich, Switzerland

⁹Department of Hematology, University of Utah, Salt Lake City, United States

¹⁰Scienze Mediche, Universita di Torino, Torino, Italy

¹¹Biostatistics, Kyowa Kirin Pharmaceutical Development, Inc., Princeton, United States

¹²Medical Affairs, Kyowa Kirin Asia Pacific Pte Ltd, Singapore, Singapore

¹³Medical Affairs, Kyowa Kirin Korea, Seoul, Republic of Korea

¹⁴Service de Dermatologie, Hopital Saint Louis, APHP, Inserm U976, Universite Paris7, Paris, France

POSTER LIST

PP05-12

Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the Mavoric trial

Amy Musiek¹, Sean Whittaker², Steven Horwitz³, Martine Bargot⁴, Auris Huen⁵, David Fisher⁶, Paul Haun⁷, Maarten Vermeer⁸, Takahiro Ito⁹, Karen Dwyer⁹, Fiona Herr¹⁰, Ki Hyon Kim^{11*}, Jungah Hwang¹², Youn Hee Kim¹³

¹Department of Dermatology, Washington University, St Louis, United States

²Department of Dermatology, King's College London, London, United Kingdom

³Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United States

⁴Servicede Dermatologie, Hopital Saint Louis, APHP, Inserm U976, Universite de Paris, Paris, France

⁵Department of Dermatology, MD Anderson Cancer Center, Houston, United States

⁶Department of Dermatology, Massachusetts General Hospital, Boston, United States

⁷Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States

⁸Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands

⁹Clinical Operations, Kyowa Kirin Pharmaceutical Development, Inc., Princeton, United States

¹⁰US Oncology, Kyowa Kirin Pharmaceutical Development, Inc., Princeton, United States

¹¹Medical Affairs, Kyowa Kirin Asia Pacific Pte Ltd, Singapore, Singapore

¹²Medical Affairs, Kyowa Kirin Korea, Seoul, Republic of Korea

¹³Department of Dermatology, Stanford University School of Medicine, Stanford, United States

PP05-13

Prognostic prediction of total metabolic tumor volume in lymphoma patients

Rabia Seyma Oz^{1*}, Ibrahim Celalettin Haznedaroglu², Umit Yavuz Malkan²

¹Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Türkiye

²Hematology, Hacettepe University Faculty of Medicine, Ankara, Türkiye

PP05-14

Treatment outcomes of aggressive B cell lymphoma: A single center review in Malaysia

Alvin Jung Mau Chai^{1*}, Tze Shin Leong¹, Grace Wan Chieng Lee¹, Lee Ping Chew¹

¹Hematology Unit, Department of Medicine, Sarawak General Hospital, Kuching, Malaysia

PP05-15

Prognostic role of 18F-FDG PET/CT in diagnosis and response evaluation of primary central nervous system lymphoma

Hyungwoo Cho¹, Minyoung Oh², Ji Eun Park³, Heounjeong Go⁴, Chan Sik Park⁴, Sang-Wook Lee⁵, Sang Woo Song⁶, Young Hyun Cho⁶, Young-Hoon Kim⁶, Seok Ho Hong⁶, Jeong Hoon Kim⁶, Dong Yun Lee², Jin-Sook Ryu², Dok Hyun Yoon^{1*}, Jae Seung Kim²

¹Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

²Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

³Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

⁴Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

⁵Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

⁶Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

POSTER LIST

- PP05-16** **Association of interleukin-2 330 T/G gene polymorphism with the risk of non-Hodgkin lymphoma: A meta-analysis**
Batara Bisuk^{1*}, William Djauhari², Shania Sondang Ni Bulan³
¹Internal Medicine, Weda General Hospital, Weda, Indonesia
²Internal Medicine, Eka Hospital BSD, BSD, Indonesia
³Internal Medicine, Sipirok General Hospital, Sipirok, Indonesia
- PP05-17** **Nodal marginal zone lymphoma accompanied by in situ follicular neoplasia with t(14;18) (q32;q21)**
Thien Dang
Histopathology, Blood Transfusion and Hematology Hospital, Ho Chi Minh, Vietnam
- PP05-18** **Clinicopathological and genetic landscape of plasmablastic lymphoma in Taiwan**
Shih-Sung Chuang^{1*}, Bo-Jung Chen², Tsung-Han Hsieh²
¹Pathology, Chi-Mei Medical Center, Tainan, Taiwan
²Pathology, Taipei Medical University, Taipei, Taiwan
- PP05-19** **Report on initial results of treating diffuse large B-cell lymphoma with polatuzumab vedotin based regimen at Vinmec times city international hospital**
Thi-Nga Nguyen^{1*}, Truc Phan^{1,2}, Trang Dao Thi Thu¹, Hyeon-Gyu Yi^{1,2}
¹Department of Hematology and Oncology, Vinmec Times city International Hospital, Hanoi, Vietnam
²College of Health Science, VinUniversity, Hanoi, Vietnam
- PP05-20** **Emergence of EBV-positive diffuse large B-cell lymphoma five years later after a previous complete remission from EBV-positive classic Hodgkin lymphoma in an HIV-infected patient**
Shih-Sung Chuang^{1*}, Chaohsun Chen²
¹Pathology, Chi-Mei Medical Center, Tainan, Taiwan
²Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan
- PP05-21** **HIV-related lymphomas in Taiwan: A retrospective study of 63 cases showing a wide spectrum of histopathology**
Shih-Sung Chuang^{1*}, Wei-Li Ma^{2,4}, Shang-Ju Wu^{3,5}
¹Pathology, Chi-Mei Medical Center, Tainan, Taiwan
²Oncology, National Taiwan University Hospital, Taipei, Taiwan
³Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
⁴Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan
⁵Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan

POSTER LIST

PP05-22

Real-world experience with zanubrutinib treatment for patients with previously treated Waldenstrom macroglobulinemia

Ja Min Byun¹, Youngil Koh^{1*}, Sung-Soo Yoon¹

¹Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

PP05-23

Machine learning based prediction of 5-year survival outcome in patients with low grade B cell lymphoma

Tong Yoon Kim¹, Gi June Min², Seok-Goo Cho², Seoree Kim³, Jong Hyuk Lee⁴, Byung-Su Kim⁵, Joon Won Jeoung⁶, Hye Sung Won⁷, Young-Woo Jeon^{1*}

¹Department of Hematology, Yeoido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Republic of Korea

²Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Republic of Korea

³Department of Oncology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Bucheon, Republic of Korea

⁴Department of Hematology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Incheon, Republic of Korea

⁵Department of Hematology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Republic of Korea

⁶Department of Oncology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Daejeon, Republic of Korea

⁷Department of Oncology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Uijeongbu, Republic of Korea

PP05-24

Comparative analysis of the clinical outcomes and measurable residual disease in CLL patients treated with FCR chemoimmunotherapy followed by ibrutinib

Tong Yoon Kim¹, Gi June Min², Young-Woo Jeon¹, Sung-Soo Park², Silvia Park², Seung-Hawn Shin³, Seung-Ah Yahng⁴, Jae-Ho Yoon², Sung-Eun Lee², Byung-Sik Cho², Yoo-Jin Kim², Seok Lee², Hee-Je Kim², Chang-Ki Min², Jong-Wook Lee², Ki-Seong Eom^{2*}

¹Department of Hematology, Yeoido St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Republic of Korea

²Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Republic of Korea

³Department of Hematology, Eunpyeong St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Republic of Korea

⁴Department of Hematology, Incheon St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea, Seoul, Republic of Korea

POSTER LIST

PP05-25

Challenges in overcoming advanced stage or relapsed refractory extra-nodal NK/T cell lymphoma, nasal type: Meta-analysis of individual patient data

Tong Yoon Kim^{1,2}, Tae Jung Kim³, Eun Ji Han⁴, Gi June Min^{2,5}, Youngwoo Jeon^{1,2}, Seok Goo Cho^{2,5*}

¹Department of Hematology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Republic of Korea

²Department of Hematology, Lymphoma and Cell Therapy Research Center, Seoul, Republic of Korea

³Department of Hospital Pathology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Republic of Korea

⁴Division of Nuclear Medicine, Department of Radiology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Republic of Korea

⁵Hematology, Seoul St. Mary's Hospital, College of Medicine, Seoul, Republic of Korea

PP05-26

Epigenetic method for determining the subtype of mantle cell lymphoma

Aleksei Bigildeev^{1*}, Dmitriy Karpenko¹, Svetlana Tsygankova¹, Evgenia Bulygina¹, Daria Koroleva², Evgeny Zvonkov²

¹Laboratory of Epigenetic Regulation of Hematopoiesis, National Medical Research Center for Hematology, Moscow, Russian Federation (Russia), Moscow, Russian Federation

²Department of Hematology and Lymphoma Chemotherapy with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit, National Medical Research Center for Hematology, Moscow, Russian Federation (Russia), Moscow, Russian Federation

PP05-27

Mutational profile of aggressive natural killer cell leukemia

Ju Hyeong Lee¹, Ja-Yoon Gu², Yujin Jung¹, Sooyong Park¹, Yoon Hwan Chang¹, Hongseok Yun³, Hyun Kyung Kim^{1,2*}

¹Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

²Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

³Department of Genomic Medicine, Seoul National University Hospital, Seoul, Republic of Korea

PP05-28

The role of hematopoietic stem cell transplantation in aggressive monomorphic epitheliotropic intestinal T-cell lymphoma

Gi June Min¹, Seok-Goo Cho^{1*}, Young-Woo Jeon², Tong Yoon Kim², Byung-Su Kim³, Daehun Kwag¹, Sung-Soo Park¹, Silvia Park¹, Jae-Ho Yoon¹, Sung-Eun Lee¹, Byung-Sik Cho¹, Ki-Seong Eom¹, Yoo-Jin Kim¹, Seok Lee¹, Hee-Je Kim¹, Chang-Ki Min¹, Jong Wook Lee¹

¹Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

²Hematology, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

³Hematology, Eunpyeong St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

POSTER LIST

PP05-29

Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after 2 prior therapies: 3-year follow-up from a pivotal phase II study

Dok Hyun Yoon¹, Stephen J. Schuster^{2*}, Laurie H. Sehn³, Nancy L. Bartlett⁴, Matthew Matasar⁵, Sarit Assouline⁶, Pratyush Giri⁷, John Kuruvilla⁸, Mazyar Shadman⁹, Chan Y. Cheah¹⁰, Sascha Dietrich¹¹, Keith Fay¹², Matthew Ku¹², Loretta Nastoupil¹³, Michael C. Wei¹⁴, Shen Yin¹⁴, Iris To¹⁴, Jiangeng Huang¹⁴, Antonia Kwan¹⁴, L. Elizabeth Budde¹⁵

¹Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

²Lymphoma, University of Pennsylvania, Philadelphia, United States

³Lymphoid Cancer, The University of British Columbia, Vancouver, Canada

⁴Siteman Cancer Center, Washington University School of Medicine, St. Louis, United States

⁵Cancer, Rutgers Cancer Institute of New Jersey, New Brunswick, United States

⁶Oncology, Jewish General Hospital, Montreal, Canada

⁷Oncology, Royal Adelaide Hospital, Adelaide, Australia

⁸Oncology, Princess Margaret Cancer Centre, Toronto, Canada

⁹Oncology, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, United States

¹⁰Linear Clinical Research, Sir Charles Gairdner Hospital, Nedlands, Australia and The University of Western Australia, Perth, Australia

¹¹Oncology, Universitat Heidelberg, Heidelberg, Germany

¹²Oncology, St Vincent's Hospital and Royal North Shore Hospital, Sydney, Australia

¹³Oncology, St Vincent's Hospital, University of Melbourne, Melbourne, Australia

¹⁴Oncology, MD Anderson Cancer Center, Houston, United States

¹⁵Oncology, Genentech, Inc., South San Francisco, United States

¹⁶Oncology, City of Hope National Medical Center, Duarte, United States

PP05-30

Clinical profile and survival of non-Hodgkin lymphoma patients at tertiary hospital in Bali, Indonesia

Ni Made Renny Anggreni Rena

Department of Internal Medicine, Hematology and Medical Oncology Division, Prof Ngoerah General Hospital, Denpasar, Bali, Indonesia

PP05-31

Double inhibition of EZH2 and EGFR/HER2: A new strategy for Burkitt lymphoma therapy

Yurim Jeong¹, Se Been Kim¹, Chae-Eun Yang¹, Minseo Yu¹, Jung-Yeon Lim¹, Youngwoo Jeon^{2*}

¹Department of Biomedical Laboratory Science, Inje University, Gimhae, Republic of Korea

²Department of Hematology, Lymphoma and Cell-therapy Research Center, Yeouido St. Mary Hospital, School of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

POSTER LIST

PP05-32

Analysis of outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma exhibiting CD20 loss

Jiwon Lee¹, Kunye Kwak¹, Min Ji Jeon², Eun Sang Yu², Dae Sik Kim², Byung-Hyun Lee³, Se Ryeon Lee³, Hwa Jung Sung³, Chul Won Choi², Yong Park¹, Byung Soo Kim¹, Ka-Won Kang^{1*}

¹Hematology, Korea University Anam Hospital, Seoul, Republic of Korea

²Hematology, Korea University Kuro Hospital, Seoul, Republic of Korea

³Hemato, Korea University Ansan Hospital, Ansan, Republic of Korea

PP05-33

The novel eIF4A inhibitor potently synergizes with BCL2 inhibitor in high grade B-cell lymphoma with MYC and BCL2 rearrangements through inhibition of UPR

Soyoung Seo¹, Soo-Jeong Kim³, Haerim Chung², Hyunsoo Cho², Jin Seok Kim², Yu Ri Kim^{1*}

¹Department of internal medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

²Department of internal medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

³Department of internal medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

PP05-34

Clinical impact of sarcopenia for first-line chemotherapy in newly diagnosed NHL patients

Cheol Sik Kim¹, Do Young Kim¹, Ho Jin Shin^{1*}

¹Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea

PP06-1

Decoding the genomic landscape of blastic plasmacytoid dendritic cell neoplasm (BPDCN): Insights into DNMT3A and TP53 mutations, MYC pathway activation, and therapeutic opportunities

Sahnaz Vivinda Putri^{1*}, Andi Nursanti Andi Ureng², Elfiany Syafruddin³, Tata Larasati⁴

¹Health Management Laboratory, International University Semen Indonesia, Gresik, Indonesia

²Pharmacy, Andini Persada College Health Sciences, Majene, Indonesia

³Computational Science, Muhammadiyah Bulukumba University, Bulukumba, Indonesia

⁴Hematology Research Unit, Dg Radja Hospital, Bulukumba, Indonesia

PP07-1

Characteristics of regulatory T cell populations expressing checkpoint receptors PD-1 and TIM-3 in multiple myeloma patients

Egor Batorov^{1,2*}, Vera Denisova³, Tatiana Aristova³, Svetlana Sizikova³, Galina Ushakova³, Dariya Batorova³, Alexandr Ostanin¹, Elena Chernykh¹

¹Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

²V. Zelman Institute of Medicine and Psychology, Novosibirsk National Research State University, Novosibirsk, Russian Federation

³Department of Hematology and Bone Marrow Transplantation, Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

POSTER LIST

PP07-2

Clinical characteristics of multiple myeloma at young age for early detection screening

Erra Nirmala Tsalistiyagita^{1*}, Prita Murani Nugraheti²

¹Universitas Islam Indonesia, Yogyakarta, Indonesia

²Clinical Pathology, Universitas Islam Indonesia, Yogyakarta, Indonesia

PP07-3

Longitudinal correlative profiles of responders, non-responders, and those with relapse on treatment with teclistamab in the MajesTEC-1 study

Deeksha Vishwamitra^{1*}, Sheri Skerget¹, Diana Cortes-Selva¹, Tatiana Perova¹, Onsay Lau¹, Cuc Davis¹, Yue Guo¹, Xin Miao¹, Tara Stephenson¹, Caroline Hodin², Clarissa Uhlar¹, Danielle Trancucci³, Kate Chastain³, Nizar Bahlis⁴, Niels W. C. J. Van De Donk⁵, Raluca Verona¹, Soomin Yoon⁶

¹Research & Development, Janssen, Spring House, PA, United States

²Research & Development, Janssen BE, Antwerp, Belgium

³Research & Development, Janssen, Raritan, NJ, United States

⁴Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada

⁵Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

⁶Medical Affairs, Janssen Korea, Seoul, Republic of Korea

PP07-4

JS-K, a nitric acid donor, mediated attenuation of autophagic flux alleviates multiple myeloma pathogenesis via induction of microRNA-144: A novel therapeutic approach

Nidhi Gupta¹, Shraddha Kapoor¹, Alpana Sharma^{1*}

¹Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, India, New Delhi, India

PP07-5

Real-world effectiveness and safety of intravenous daratumumab in patients with multiple myeloma: A multi-center, observational study from Korea

Youngil Koh¹, Sung-Soo Yoon¹, Je-Jung Lee², Kihyun Kim³, Sung-Hoon Jung², Sung-Soo Park⁴, Sang Eun Yoon³, Youngju Park⁵, Soomin Yoon⁵, Chang-Ki Min^{4*}

¹Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea

²Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Republic of Korea

³Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

⁴Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

⁵Medical Affairs, Janssen Korea Ltd, Seoul, Republic of Korea

POSTER LIST

PP07-6

Enhancing the survival of patients with primary plasma cell leukemia and identification of prognostic factors: Insights from a comprehensive study (the KMMWP-2204 study)

Mihee Kim¹, Je-Jung Lee¹, Hee Jeong Cho², Dae Sik Kim³, Jongheon Jung⁴, Ji Hyun Lee⁵, Kihyun Kim⁶, Ja Min Byun⁷, Dok Hyun Yoon⁸, Yoon Seok Choi⁹, Jae-Cheol Jo¹⁰, Ho-Young Yhim¹¹, Myung-Won Lee¹², Sung-Nam Lim¹³, Jae Hoon Lee¹⁴, Sung-Soo Park¹⁵, Sung-Hoon Jung^{1*}, Chang-Ki Min¹⁵

¹Hematology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea

²Hematology, Kyungpook National University Hospital, Daegu, Republic of Korea

³Hematology, Korea University Guro Hospital, Seoul, Republic of Korea

⁴Hematology, National Cancer Center, Goyang, Republic of Korea

⁵Hematology, Dong-A University College of Medicine, Busan, Republic of Korea

⁶Hematology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea

⁷Hematology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

⁸Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

⁹Hematology, Ajou University School of Medicine, Suwon, Republic of Korea

¹⁰Hematology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea

¹¹Hematology, Jeonbuk National University Hospital, Jeonju, Republic of Korea

¹²Hematology, Chungnam National University Hospital, Daejeon, Republic of Korea

¹³Hematology, Inje University College of Medicine, Busan, Republic of Korea

¹⁴Hematology, Gachon University Gil Medical Center, Incheon, Republic of Korea

¹⁵Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

PP07-7

Fractures and mortality in multiple myeloma patients: A Korean population-based case-control study (the CAREMM-2105 study)

Jeonghoon Ha^{1,2}, Suein Choi^{3,4}, Sung-Soo Park^{5,6*}, Seulji Moon^{3,4}, Jinseon Han^{3,4}, Jeongyoon Lee^{3,4}, Ki-Hyun Baek^{2,7}, Seunghoon Han^{3,4}, Chang-Ki Min^{5,6}

¹Internal Medicine, Seoul St. Mary's Hospital, Seoul, Republic of Korea

²Catholic Medical Center Bone Research Group, The Catholic University of Korea, Seoul, Republic of Korea

³Pharmacology, The Catholic University of Korea, Seoul, Republic of Korea

⁴Pharmacometrics Institute for Practical Education and Training (PIPET), The Catholic University of Korea, Seoul, Republic of Korea

⁵Hematology, Seoul St. Mary's Hematology Hospital, Seoul, Republic of Korea

⁶Catholic Research Network for Multiple Myeloma, The Catholic University of Korea, Seoul, Republic of Korea

⁷Internal Medicine, Yeouido St. Mary's Hospital, Seoul, Republic of Korea

POSTER LIST

PP07-8

Cardiovascular disease in long-term multiple myeloma survivors: A nationwide Korean case-control study (the CAREMM-2105 study)

Suein Choi^{1,2}, Jeonghoon Ha⁵, Sung-Soo Park^{3,4*}, Seunghoon Han^{1,2}, Chang-Ki Min^{3,4}

¹Department of Pharmacology, The Catholic University of Korea, Seoul, Republic of Korea

²Pharmacometrics Institute for Practical Education and Training, The Catholic University of Korea, Seoul, Republic of Korea

³Seoul St. Mary's Hematology Hospital, The Catholic University of Korea, Seoul, Republic of Korea

⁴Leukemia Research Institute, The Catholic University of Korea, Seoul, Republic of Korea

⁵Department of Internal Medicine, The Catholic University of Korea, Seoul, Republic of Korea

PP07-9

Favorable survival outcomes with delayed treatment in multiple myeloma patients with biochemical relapse

Hyukjin Choi¹, Joon Ho Moon^{1*}, Sang-Kyun Sohn¹, Dong Won Baek¹, Hee Jeong Cho¹, Ju-Hyung Kim¹, Myung Won Lee²

¹Department of Hematology-Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea

²Department of Hematology-Oncology, Chungnam National University Hospital, School of Medicine, Chungnam National University, Chungnam, Republic of Korea

PP07-10

The significance of galectin-3 level in plasma cell proliferations complicated by kidney damage

Zhanna Kozich^{1*}, Viktor Martinkov¹, Janna Pugacheva¹, Nataliya Klimkovich²

¹Hematology Department, Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus

²Hematology Department, Belarusian Medical Academy for Postgraduate Education, Minsk, Belarus

POSTER LIST

PP07-11

A phase 3, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-1

Paul G. Richardson¹, Sorina N. Badelita², Britta Besemer³, Jean-Samuel Boudreault⁴, Ja Min Byun^{5*}, Claudio Cerchione⁶, Moshe E. Gatt⁷, Simon Gibbs⁸, Junya Kuroda⁹, Joaquin Martinez-Lopez¹⁰, Chang-Ki Min¹¹, Robert Z. Orlowski¹², Hang Quach¹³, Marc S. Raab¹⁴, Katja Weisel¹⁵, Xin Zhou¹⁶, Michael Amatangelo¹⁷, Yue Wang¹⁷, Soo Jeong Hwang¹⁷, Jessica Katz¹⁷

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States

²Department of Hematology, Fundeni Clinical Institute, Bucharest, Romania

³Department of Hematology, Oncology, Immunology, and Rheumatology, University Hospital of Tübingen, Tübingen, Germany

⁴Division of Hematology and Oncology, Department of Medicine, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada

⁵Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea

⁶Hematology Unit, Istituto Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

⁷Department of Hematology, Hadassah Medical Center, Jerusalem, Israel

⁸Department of Haematology, Box Hill Hospital, Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia

⁹Department of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan

¹⁰Department of Hematology, Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid, Spain

¹¹Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

¹²Department of Lymphoma & Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States

¹³Department of Haematology, St. Vincent's Hospital Melbourne, University of Melbourne, Melbourne, VIC, Australia

¹⁴Department of Hematology, Universitätsklinikum Heidelberg, Heidelberg, Germany

¹⁵Department of Hematology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany

¹⁶Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China

¹⁷Research and Development, Bristol Myers Squibb, Princeton, NJ, United States

POSTER LIST

PP07-12

EXCALIBER-RRMM: A phase 3, 2-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVD) in patients with relapsed/refractory multiple myeloma (RRMM)

Sagar Lonial¹, Hang Quach², Meletios Dimopoulos³, Paula Rodriguez Otero⁴, Jesus Berdeja⁵, Paul Richardson⁶, Margee Kyada⁷, Shuyu Chu⁷, Min Chen⁷, Patricia Abad⁷, Juliane Morando⁷, Kihyun Kim^{9*}, Niels Van De Donk⁸

¹Hematology & Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States

²Clinical Haematology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia

³Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece

⁴Haematology & Haemotherapy, Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain

⁵Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, United States

⁶Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States

⁷Research & Development, Bristol Myers Squibb, Princeton, NJ, United States

⁸Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands

⁹Medicine, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea

PP07-13

Non-clinical test results of tetracyclic triterpene compound, a new effective drug candidate for multiple myeloma treatment

Hye Ran Kim^{1,4}, Young Eun Lee^{2,4}, Ha Jin Lim², Yong Jun Choi², Joo Heon Park², Jong Hee Shin², Myung Geun Shin^{2,3,4*}

¹College of Korean Medicine, Dongshin University, Naju, Republic of Korea

²Department of Laboratory Medicine, Chonnam National University and Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea

³BioMedical Sciences Graduate Program (BMSGP), Chonnam National University and Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea

⁴Department of Research and Development, KBlueBio Inc., Hwasun, Republic of Korea

PP07-14

Glutathione S-transferase M1 and T1 deletion mutation is associated with the risk of multiple myeloma development: A meta-analysis

Arch Raphael Manalac^{1*}, Francheska Casupan¹, Arlene Joy Canasa¹, Angela Mae Cuartelon¹, Justine Nicole Sison¹, Janina Carla Zapata¹, Raphael Enrique Tiongco¹

¹College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines

POSTER LIST

PP07-15

MagnetisMM-3 trial: Updated long-term efficacy and safety of elranatamab in relapsed or refractory multiple myeloma

Shinsuke Iida^{1*}, Michael H. Tomasson², Ruben Niesvizky³, Mohamad Mohty⁴, Nizar J. Bahlis⁵, Joaquin Martinez-Lopez⁶, Guenther Koehne⁷, Paula Rodriguez-Otero⁸, H. Miles Prince⁹, Andrea Viqueira¹⁰, Eric Leip¹¹, Umberto Conte¹², Sharon T. Sullivan¹¹, Alexander M. Lesokhin¹³, Young-Mee Kim¹⁵

¹Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

²Department of Internal Medicine, University of Iowa, Iowa City, United States

³Clinical Medicine: Hematology/Oncology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, United States

⁴Hopital Saint-Antoine and INSERM UMRS938, Sorbonne University, Paris, Gabon

⁵Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada

⁶Servicio de Hematología y Hemoterapia, Hospital Universitario 12 de Octubre, Madrid, Spain

⁷Blood & Marrow Transplant and Hematologic Oncology, Miami Cancer Institute, Miami, United States

⁸Central Unit for Clinical Trials, Clínica Universidad de Navarra, Madrid, Spain

⁹Clinical Haematology, Epworth Healthcare and University of Melbourne, Melbourne, Australia

¹⁰Clinical Oncology, Pfizer SLU, Madrid, Spain

¹¹Department of Clinical Research, Pfizer, Inc., Cambridge, United States

¹²Clinical Oncology, Pfizer Inc, Cambridge, United States

¹³Clinical Oncology, Pfizer Inc, New York, United States

¹⁴Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, United States

¹⁵Medical, Pfizer Korea, Seoul, Republic of Korea

PP07-16

Clinicopathological characteristics of monoclonal gammopathy of clinical significance in a single tertiary hospital

Sooyong Park¹, Hyun Kyung Kim¹, Yoon Hwan Chang^{1*}

¹Laboratory Medicine, Seoul National University Hospital, Seoul, Republic of Korea

POSTER LIST

PP07-17

Retrospective analysis of autologous stem cell transplantation treatment outcomes in patients with dialysis-dependent multiple myeloma (DDMM) : KMM2304 study

Myung-Won Lee¹, Sung-Hoon Jung², Chang-Ki Min³, Ho-Young Yhim⁴, Dok Hyun Yoon⁵, Sang Min Lee⁶, Ho-Jin Shin⁷, Jae-Cheol Jo⁸, Jongheon Jung⁹, Yundeok Kim¹⁰, Jae Hoon Lee¹¹, Ji Hyun Lee¹², Sunghyun Kim¹², Jieun Uhm¹³, Kihyun Kim^{14*}

¹Division of Hematology and Oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea

²Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Jeollanam-do, Republic of Korea

³Hematology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea

⁴Division of Hematology/Oncology, Department of Internal Medicine, Jeonbuk National University Hospital, Jeonju, Republic of Korea

⁵Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

⁶Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Republic of Korea

⁷Division of Hematology-Oncology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea

⁸Department of Hematology-Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea

⁹Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, Republic of Korea

¹⁰Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea

¹¹Division of Hematology, Gachon University College of Medicine Gil Medical Center, Incheon, Republic of Korea

¹²Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Republic of Korea

¹³Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea

¹⁴Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea

PP07-18

Increase of regulatory T cells in multiple myeloma

Hee Sue Park^{1,2}, Bo Ra Son^{1,2}, Yong-Pyo Lee^{3,4}, Jihyun Kwon^{3,4*}

¹Laboratory Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea

²Laboratory Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea

³Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea

⁴Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea

POSTER LIST

PP07-19

Distinct single-cell RNA sequencing-based transcriptional phenotype for AL amyloidosis Sung-Soo Park^{1,2}, Ji-Young Lim^{1,2}, Jung Yeon Lee^{1,2}, Seung-Hyun Jung³, Chang-Ki Min^{1,2*}

¹Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Catholic Research Network for Multiple Myeloma, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

³Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

PP07-20

Real-world outcomes of novel immunotherapy versus standard of care in patients with relapsed/refractory multiple myeloma (CAREMM-2305) Seung-Hwan Shin^{1,6}, Sung-Soo Park^{2,6}, Su-Ein Choi³, Seung-Hoon Han³, Jeong Yeon Lee^{2,6}, Seung-Ah Yahng^{3,6}, Young-Woo Jeon^{4,6}, Chang-Ki Min^{2,6}

¹Myeloma Center, Hematology Institute, Eunpyeong St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

²Department of Hematology, Seoul St. Mary's Hematology Hospital, The Catholic University of Korea, Seoul, Republic of Korea

³Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

⁴Department of Hematology, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea

⁵Department of Hematology, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea

⁶Catholic Research Network for Multiple Myeloma, Catholic Hematology Hospital, The Catholic University of Korea, Seoul, Republic of Korea

PP07-21

Exploration of clinical implication of circulating tumor DNA in multiple myeloma and its precursor diseases Sung-Soo Park^{1,2}, Seung-Hyun Jung³, Ji-Young Lim^{1,2}, Jung Yeon Lee^{1,2}, Chang-Ki Min^{1,2*}

¹Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Catholic Research Network for Multiple Myeloma, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

³Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

PP08-1

The TERT rs2736100 polymorphism as genetic predisposition of myeloproliferative neoplasms in Asian population: A systematic review and meta-analysis Alfateya Pintari Rahmi^{1*}, Tohari Tohari², Anindia Reina Yolanda³, Shinta Oktya Wardhani⁴

¹Medical Faculty, Universitas Brawijaya, Malang, Indonesia

²Internal Medicine Department, Universitas Brawijaya, Malang, Indonesia

³Emergency Department, Lavalette Hospital, Malang, Indonesia

⁴Hemato-Oncology Division of Internal Medicine Department, Universitas Brawijaya, Malang, Indonesia

POSTER LIST

PP08-2

Molecular profile of myeloproliferative neoplasms

Jiyeon Kim¹, Yu Jeong Choi¹, Haerim Chung², Hye Won Kook², Ji Eun Jang², Doh Yu Hwang², Seung-Tae Lee¹, Jong Rak Choi¹, June-Won Cheong², Saeam Shin^{1*}

¹Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

PP08-3

Targeting c-Abl in myeloproliferative neoplasms: Benzylisoquinoline derivatives and their inclusion complexes form by molecular docking/ ADMET profiles

Rizki Rachmad Saputra¹, Reny Rosalina^{1*}

¹Department of Chemistry, Universitas Palangka Raya, Palangka Raya, Indonesia

PP08-4

Combination of hydroxyurea and anagrelide as first-line treatment for patients with essential thrombocythemia

Young Hoon Park^{1*}, Sewon Lee¹, Seonggyu Byeon², Hana Kim², Kyoo-Hyung Lee¹, Yeung-Chul Mun¹

¹Division of Hematology/Oncology, Department of Internal Medicine, Ewha Womans University Medical Center Mokdong Hospital, Seoul, Republic of Korea

²Division of Hematology/Oncology, Department of Internal Medicine, Ewha Womans University Medical Center Seoul Hospital, Seoul, Republic of Korea

PP08-5

Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study

Joon Young Hur¹, Nayeon Choi², Jung Hye Choi¹, Jiyeong Kim^{2,3}, Young-Woong Won^{1*}

¹Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Republic of Korea

²Biostatistical Consulting and Research Lab, Hanyang University, Seoul, Republic of Korea

³Department of Pre-Medicine, Hanyang University, Seoul, Republic of Korea

PP08-6

Clinical features and outcomes of JAK2 unmutated erythrocytosis

Jeong Suk Koh¹, Sora Kang¹, Myung-Won Lee¹, Hyewon Ryu¹, Ik-Chan Song¹, Hyo-Jin Lee¹, Hwan-Jung Yun¹, Deog-Yeon Jo^{1*}

¹Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea

POSTER LIST

- PP08-7** **JAK2V617F, CALR and MPL mutation profiles in patients with myeloproliferative neoplasms, northeast Thailand**
Kanokon Chootawiriyasakul^{1*}, Chinadol Wanitpongpun², Prajuab Chaimanee³, Pimjai Anata³, Pinsuda Klangsang¹
¹Department of Medicine, The clinical laboratory of Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand, Khon Kaen 40002, Thailand, Thailand
²Department of Medicine, Hematology Unit Department of Medicine, Faculty of Medicine, Khon Kaen University Khon Kaen 40002, Thailand, Khon Kaen 40002, Thailand, Thailand
³Clinical Laboratory, Srinagarind Hospital, Khon Kaen University, Molecular Diagnosis Unit, Clinical Laboratory, Srinagarind Hospital, Khon Kaen University, Khon Kaen 40002, Thailand, Khon Kaen 40002, Thailand, Thailand
- PP08-8** **A pilot project to assess genotoxicity induced by hydroxyurea in patients with JAK2 positive polycythemia vera**
Senani Williams
Pathology, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka
- PP08-9** **Progression of carotid plaque burden in patients with polycythemia vera and essential thrombocythemia**
Seug Yun Yoon, Sun Young Jeong, Min-Young Lee, Kyoung Ha Kim, Namsu Lee, Jong-Ho Won^{*}
¹Division of Hematology & Medical Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea
- PP09-1** **Next generation sequencing is vital for accurate genotyping in inherited bone marrow failure syndromes**
Ganesh Kumar Viswanathan^{1*}, Jasmita Dass¹, Richa Chauhan¹, Rishi Dhawan¹, Mukul Aggarwal¹, Pradeep Kumar¹, Manoranjan Mahapatra¹
¹Hematology, All India Institute of Medical Sciences (AIIMS), New Delhi, New Delhi, India
- PP09-2** **The frequency of clonal T cells and its correlation with clinical and laboratory parameters in adult-onset aplastic anemia**
Sudhanshi Raina¹, Abhishek Asthul¹, Arihant Jain¹, Anand Balakrishnan¹, Praveen Sharma¹, Pramod Kumar¹, Prabhjot Kaur¹, Man Updesh Singh Sachdeva¹, Pankaj Malhotra¹, Alka Khadwal¹, Sreejesh Sreedharanunni^{1*}
¹Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
- PP09-3** **Establishing reference range for relative telomere length in normal Indian individuals**
Sudhanshi Raina^{1*}, Prabhjot Kaur¹, Pradeep Reddy¹, Shilpa Amatyia¹, Anand N Balakrishna¹, Man Updesh Singh Sachdeva¹, Prateek Bhatia¹, Amita Trehan¹, Arihant Jain¹, Rekha Hans¹, Anup Ghosh¹, Pankaj Malhotra¹, Reena Das¹, Sreejesh Sreedharanunni¹
¹Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

POSTER LIST

PP09-4

Efficacy and safety of ATG + CsA + romiplostim for untreated aplastic anemia: A phase 2/3 clinical trial

Jun Ho Jang¹, Masashi Sawa², Jong Wook Lee³, Hirohito Yamazaki⁴, Masahiro Kizaki⁵, Yoshiaki Tomiyama⁶, Koji Nagafuji⁷, Kensuke Usuki⁸, Jyh-Pyng Gau⁹, Yasuyoshi Morita¹⁰, Jih-Luh Tang¹¹, Hung Chang¹², Masayoshi Noshiro¹³, Akira Matsuda¹⁴, Keiyo Ozawa¹⁵, Kinuko Mitani¹⁶, Yoshinobu Kanda¹⁵, Jungah Hwang¹⁷, Ki Hyon Kim¹⁸, Shinji Nakao^{4*}

¹Department of Hematology, Samsung Medical Center, Seoul, Republic of Korea

²Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan

³Division of Hematology, Seoul St. Mary's Hospital, Seoul, Republic of Korea

⁴Division of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan

⁵Department of Hematology, Saitama Medical Center, Saitama, Japan

⁶Department of Blood Transfusion, Osaka University Hospital, Osaka, Japan

⁷Department of Pathology, Kurume University Hospital, Fukuoka, Japan

⁸Department of Hematology, NTT Medical Center, Tokyo, Japan

⁹Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

¹⁰Department of Medicine, Kindai University Faculty of Medicine, Higashiosaka, Japan

¹¹Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

¹²Department of Laboratory Medicine, Chang Gung Medical Foundation Linkou Branch, Taoyuan, Taiwan

¹³Medical Affairs, Kyowa Kirin Co., Ltd., Tokyo, Japan

¹⁴Department of Hematology, Saitama Medical University International Medical Center, Saitama, Japan

¹⁵Department of Medicine, Jichi Medical University, Tochigi, Japan

¹⁶Department of Hematology, Dokkyo Medical University Hospital, Tochigi, Japan

¹⁷Medical Affairs, Kyowa Kirin Korea, Seoul, Republic of Korea

¹⁸Medical Affairs, Kyowa Kirin Asia Pacific Pte Ltd, Singapore, Singapore

POSTER LIST

PP09-5

Efficacy and safety of romiplostim combined with cyclosporine A as a first-line treatment in patients with aplastic anemia: A phase 2/3 clinical trial

Jun Ho Jang¹, Shigeru Chiba², Jong Wook Lee³, Sung Soo Yoon⁴, Gaku Oshikawa⁵, Kensuke Usuki⁶, Yeung-Chul Mun⁷, Toshiro Kawakita⁸, Kanzumori Imada⁹, June Wong Cheong¹⁰, Masayoshi Noshiro¹¹, Akira Matsude¹², Keiya Ozawa¹³, Kinuko Mitani¹⁴, Yoshinobu Kanda¹³, Jungah Hwang¹⁵, Ki Hyon Kim¹⁶, Shinji Nakao^{17*}

¹Department of Hematology, Samsung Medical Center, Seoul, Republic of Korea

²Department of Hematology, University of Tsukuba, and University of Tsukuba Hospital, Tsukuba, Japan

³Division of Hematology, Seoul St. Mary's Hospital, Seoul, Republic of Korea

⁴Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

⁵Department of Hematology, Japan Red Cross Musashino Hospital, Tokyo, Japan

⁶Department of Hematology, NTT Medical Center, Tokyo, Japan

⁷Department of Internal Medicine, Ewha Womans' University College of Medicine, Seoul, Republic of Korea

⁸Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan

⁹Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan

¹⁰Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

¹¹Medical Affairs, Kyowa Kirin Co. Ltd, Tokyo, Japan

¹²Department of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan

¹³Department of Medicine, Jichi Medical University, Tochigi, Japan

¹⁴Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

¹⁵Medical Affairs, Kyowa Kirin Korea, Seoul, Republic of Korea

¹⁶Medical Affairs, Kyowa Kirin Asia Pacific Pte Ltd, Singapore, Singapore

¹⁷Department of Hematology, Kanazawa University, Kanazawa, Japan

PP09-6

Report of the first Delphi round of the ongoing Asian aplastic anemia recommendation development: An evidence- and opinion-based consensus

Jun Ho Jang¹, Yok-Lam Kwong², Surapol Issaragrisil³, Kohei Hosokawa⁴, Ming Yao⁵, Yeu-Chin Chen⁶, Yeung-Chul Mun⁷, Feng-Kui Zhang⁸, Lily Wong⁹, Shinji Nakao^{10*}

¹Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea

²Division of Hematology, Oncology and Bone Marrow Transplantation at the Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong

³Division of Hematology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

⁴Division of Hematology, Kanazawa University Hospital, Kanazawa City, Japan

⁵Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

⁶National Defence Medical Center, Taipei, Taiwan

⁷Ewha Women's University Mokdong Hospital, Seoul, Republic of Korea

⁸Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Chief Physician, Tianjin, China

⁹Department of Hematology, Queen Elizabeth Hospital, Head of Department, Kota Kinabalu, Sabah, Malaysia

¹⁰Japanese Red Cross Ishikawa Blood Centre, Kanazawa City, Japan

POSTER LIST

PP09-7

Safety of SB12 (eculizumab biosimilar) in Asian and non-Asian patients with paroxysmal nocturnal hemoglobinuria: Subgroup analysis of a global phase III randomized controlled trial

Jun Ho Jang^{1*}, Jihye Park², Younsoo Kim², Sungil Ju², Jake Yongkwon Lee², Paola Russo²

¹Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Seoul, Republic of Korea

²Samsung Bioepis, Incheon, Republic of Korea

PP10-1

Red cell enzymopathies in Indians: Molecular spectrum and diagnostic approach in unexplained hemolytic anemias

Ravina Taak¹, Manu Jamwal¹, Prashant Sharma¹, Deepak Bansal², Pankaj Malhotra³, Arindam Maitra⁴, Reena Das^{1*}

¹Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

²Pediatric, Postgraduate Institute of Medical Education and Research, Chandigarh, India

³Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

⁴Human Genomics, National Institute of Biomedical Genomics, Kalyani West Bengal, India

PP10-2

Genotype analysis and clinical outcome in Indian patients with rare congenital anemias

Manu Jamwal¹, Anu Aggarwal¹, Prashant Sharma¹, Deepak Bansal², Amita Trehan², Pankaj Malhotra³, Arindam Maitra⁴, Reena Das^{1*}

¹Hematology, PGIMER, Chandigarh, India

²Pediatrics, PGIMER, Chandigarh, India

³Clinical Hematology and Medical Oncology, PGIMER, Chandigarh, India

⁴National Institute of Biomedical Genomics, Kalyani, West Bengal, India

PP10-3

Molecular genetic spectrum of non-transfusion-dependent beta thalassemia: A study of primary and secondary phenotype modifiers in 258 north Indian cases

Prashant Sharma^{1*}, Namrata Singh¹, Reena Das¹, Alka Rani Khadwal², Jasbir Kaur Hira¹, Sanjeev Chhabra¹, Amita Trehan³, Richa Jain³, Deepak Bansal³, Pankaj Malhotra²

¹Department of Hematology, Research Block A, Postgraduate Institute of Medical Education and Research, Chandigarh, India

²Department of Clinical Hematology and Medical Oncology, Nehru Hospital, Postgraduate Institute of Medical Education and Research, Chandigarh, India

³Pediatric Hematology/Oncology Unit, Department of Pediatric Medicine, Advanced Pediatric Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India

POSTER LIST

PP10-4

Blood count scattergrams are fingerprints of blood: Using AI to inform health status

Rana Zeeshan Haider^{1*}, Sidra Izhar², Wendy Erber³, Ikram Uddin¹

¹Diagnostic and Research Lab, Liaquat University of Medical and Health Sciences, Karachi, Pakistan

²Department of Pathology, Baqai Medical University, Karachi, Pakistan

³School of Biomedical Sciences, The University of Western Australia, Perth, Australia

PP10-5

Evaluation of diagnostic utility of CD43 and CD200 in differentiating B-cell chronic lymphoproliferative disorders by flow cytometry

Abhishek Purohit^{1*}, Gopal Krishana Bohra², Akanksha Garg³, Parmod Kumar³, Tejasvi Sharma¹,

Shruti Vaswani¹, Sharumathi E¹

¹Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, India

²General Medicine, All India Institute of Medical Sciences, Jodhpur, India

³Medical Oncology/Haematology, All India Institute of Medical Sciences, Jodhpur, India

PP10-6

Hit me, baby, one more time: The experience of learning phlebotomy using a hybrid-based approach

Juan Pio Luis Bacani¹, Ryan Charles Bermas¹, Klouie Angeline Koh¹, Timotei James Morales¹, Christine Mae Naluz¹, Nicole Justine Padillo¹, Noel Mari Yamzon¹, Julie Ann Mercado^{1*}, Raphael Enrique Tiongco¹

¹College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines

PP10-7

Low-cost LAMP-turbidimetric assay for detecting alpha(zero)-thalassemia (SEA deletion): Preventing and controlling Hb Bart's hydrops fetalis syndrome in Thailand

Wittaya Jomoui^{1*}, Kanokkorn Saknava², Kanokpron Prechatrammaruch², Yanticha Ondee²

¹Pathology, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand

²Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand

PP10-8

Influencing of alpha-thalassemia-1 to HbE and HbA2 levels separated and quantified by capillary electrophoresis system in HbE heterozygotes: Simple and rapid screening using HbE levels alone

Sitthichai Panyasai

Medical Technology, School of Allied Health Sciences, University of Phayao, Phayao, Thailand, 56000, Muang Phayao, Thailand

POSTER LIST

PP10-9

Is digital morphology analyzer reliable for white blood cell differential in body fluids?:

Performance assessment of sysmex DI-60

Eunju Shin¹, Mina Hur^{1*}, Hanah Kim¹, Mi Hyun Hong¹, Hee-Won Moon¹, Yeo-Min Yun¹, Minjeong Nam², Seungcho Lee³

¹Laboratory Medicine, Konkuk University School of Medicine, Seoul, Republic of Korea

²Laboratory Medicine, Korea University Anam Hospital, Seoul, Republic of Korea

³Preventive Medicine, Dong-A University College of Medicine, Busan, Republic of Korea

PP10-10

Multiple primary cancers with hematologic malignancies and germline predisposition: A case series

Jiwon Yun¹, Dong Soon Lee², Hongseok Yun^{3*}

¹Department of Laboratory Medicine, ChungAng University College of Medicine, Seoul, Republic of Korea

²Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

³Department of Genomic Medicine, Seoul National University Hospital, Seoul, Republic of Korea

PP10-11

Development and clinical application of targeted NGS panels for hematological malignancies covering WHO/ICC 2022 guideline

Young Eun Lee^{1,4}, Hye Ran Kim^{3,4}, Ha Jin Lim¹, Yong Jun Choi¹, Joo Heon Park¹, Hyun-Woo Choi¹, Hyun-Jung Choi¹, Seung-Jung Kee¹, Soo Hyun Kim¹, Jong Hee Shin¹, Myung Geun Shin^{1,2,4*}

¹Department of Laboratory Medicine, Chonnam National University and Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea

²BioMedical Sciences Graduate Program (BMSGP), Chonnam National University and Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea

³College of Korean Medicine, Dongshin University, Naju, Republic of Korea

⁴Department of Research and Development, KBlueBio Inc., Hwasun, Republic of Korea

PP10-12

Parasite-derived particles: A new approach to diagnose malaria

Attakorn Palasuwan

Clinical Microscopy, Oxidation in Red Cell Disorders Research Unit, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand, Bangkok, Thailand

POSTER LIST

PP10-14

Automated blood cell counter-derived unhosted cells (UGC): Exploring a novel red cell research parameter for clinical insights and diagnostic significance in diverse clinico-pathological contexts

Praveen Sharma^{1*}, Anita Giri¹, Prashant Sharma¹, Minakshi Gupta¹, Dikshat Gopal Gupta², Aashima Arora⁴, Srinivasan Peyam³, Alka Rani Khadwal⁵, Reena Das¹

¹Hematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, Chandigarh, India

²Urology, Feinberg School of Medicine, North-Western University, Chicago, United States

³Pediatrics (Pediatric Hematology-Oncology Division), Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, Chandigarh, India

⁴Obstetrics and Gynecology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, Chandigarh, India

⁵Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, Chandigarh, India

PP10-15

Plasma soluble CSF1R is a promising prognostic indicator for pediatric Langerhans cell histiocytosis

Ting Zhu^{1,2,3,4}, Chan-Juan Wang^{2,3,4}, Hong-Yun Lian^{2,3,4}, Hong-Hao Ma^{2,3,4}, Dong Wang^{2,3,4}, Tian-You Wang^{2,3,4}, Rui Zhang^{2,3,4}, Lei Cui^{1,2,3,4}, Zhi-Gang Li^{1,2,3,4*}

¹Hematologic Diseases Laboratory, Beijing Children's Hospital, Beijing, China

²Beijing Key Laboratory of Pediatric Hematology-Oncology, Beijing Children's Hospital, Beijing, China

³National Key Discipline of Pediatrics, Beijing Children's Hospital, Beijing, China

⁴Key Laboratory of Major Diseases in Children, Beijing Children's Hospital, Beijing, China

PP10-16

Predictive value of the complete blood count in determining the length of hospital stay among Filipino patients with COVID-19: A single center study

Imoan Shallom Aguas^{1,2}, Raphael Enrique Tiongco^{1,2*}, Annalyn Navarro^{1,2}

¹Graduate School, Angeles University Foundation, Angeles City, Philippines

²College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines

PP10-17

Unveiling the distinctive gene expression profile of Ph-like acute lymphoblastic leukemia

Seoyoung Lim^{1*}, Yu Jeong Choi², Saeam Shin², Seung-Tae Lee², Jong Rak Choi²

¹Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea

²Department of Laboratory Medicine, Severance Hospital, Seoul, Republic of Korea

PP10-18

Genetic differences in myelodysplastic syndrome and clonal cytopenia of undetermined significance

Kang Yehyun

Laboratory Medicine, Severance Hospital, Seoul, Republic of Korea

POSTER LIST

- PP10-19** **Clinical and molecular spectrum of DDX41 variants in Korean patients with hematologic malignancies**
Boram Kim¹, Hee-Jin Kim¹, Chul Won Jung², Jun Ho Jang², Duck Cho¹, Sun-Hee Kim¹, Hyun-Young Kim^{1*}
¹Laboratory Medicine and Genetics, Samsung Medical Center, Seoul, Republic of Korea
²Internal Medicine, Samsung Medical Center, Seoul, Republic of Korea
- PP10-20** **Clinical application of TRBC1 expression for diagnosis of T-cell lymphoma**
Sooho Yu¹, Boram Kim¹, Duck Cho¹, Hee-Jin Kim¹, Hyun-Young Kim^{1*}
¹Department of Laboratory Medicine and Genetics, Samsung Medical Center, Seoul, Republic of Korea
- PP10-21** **Hematological laboratory findings and its association with clinical spectrum of COVID-19 in pregnant women in Yogyakarta, Indonesia**
Isna Arifah Rahmawati^{1*}, Anita Rohmah^{1,2}
¹Medicine, Islamic University of Indonesia, Yogyakarta, Indonesia
²Obstetric and Gynecology, Regional General Hospital Wonosari, Yogyakarta, Indonesia
- PP12-1** **Effect of omega 3 unsaturated fatty acid supplements on perioperative bleeding after spinal surgery**
Tsanía Atika Rahma^{1*}, Ana Fauziyati²
¹Universitas Islam Indonesia, Yogyakarta, Indonesia
²Internal Medicine, Universitas Islam Indonesia, Yogyakarta, Indonesia
- PP12-2** **Insulin resistance and increased risk of pulmonary embolism in leukemia, lymphomas and related disorders**
Javad Alizargar
 Medicine, Kashan University, Isfahan, Iran, Islamic Republic of
- PP12-3** **Non-cirrhotic portal hypertension in a patient with essential thrombocythemia: A case report and literature review**
Novi Davitsen¹, Tohari Tohari^{1*}, Alfatea Rahmi³, Shinta Wardhani²
¹Internal Medicine Resident, Universitas Brawijaya, Malang, Indonesia
²Hemato-Oncology Division of Internal Medicine Department, Universitas Brawijaya, Malang, Indonesia
³Universitas Brawijaya, Malang, Indonesia
- PP12-4** **Bernard Soulier syndrome caused by two novel heterozygous mutations in GP1BA gene: A case report and literature review**
Senlin Zhang¹, Jing Ling¹, Kai Cui¹, Junjie Fan¹, Shaoyan Hu^{1*}
¹Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China

POSTER LIST

- PP12-5 Paediatric thrombosis: A five-year experience from a tertiary care center of Pakistan**
Anila Rashid
Haematology, Aga Khan University Hospital, Karachi, Pakistan
- PP12-6 Cannabinoid receptor 2 signaling: Role in megakaryocyte development and neuro-immune regulation**
Ravi Kumar Gutti
Department of Biochemistry, University of Hyderabad, Hyderabad, India
- PP12-7 Plasma levels of three different types of direct oral anticoagulants measured with anti-factor Xa assay in patients with non-valvular atrial fibrillation: Comparison with heparin assays**
Suji Park¹, Min-Sun Kwak¹, Jae-Ryong Shim¹, Kwang-Sook Woo¹, Jong-Sung Park², Dae-Hyun Kim³, Jin-Yeong Han^{1*}
¹Laboratory Medicine, Dong-A University College of Medicine, Busan, Republic of Korea
²Cardiology, Dong-A University College of Medicine, Busan, Republic of Korea
³Neurology, Dong-A University College of Medicine, Busan, Republic of Korea
- PP12-8 Evaluation of neutrophil extracellular traps as a novel circulating marker in acute ischemic stroke patients and the correlation with cytokines**
Suji Park¹, Jae-Ryong Shim¹, Dae Hyun Kim², Jin-Yeong Han^{1*}
¹Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Republic of Korea
²Department of Neurology, Dong-A University of Medicine, Busan, Republic of Korea
- PP12-9 Thrombopoietin-independent generation of platelet-like particles from megakaryoblastic cells**
Duangdao Palasuwan^{1*}, Nuntiporn Nunthanasup¹, Nutpakal Ketprasit¹, Kasem Kulkeaw², Attakorn Palasuwan¹
¹Clinical Microscopy, Oxidation in Red Cell Disorders Research Unit, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand, Bangkok, Thailand
²Siriraj Integrative Center for Neglected Parasitic Diseases, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
- PP12-10 Evaluation of FVIII PK profile in Korean hemophilia patients assessed with myPKFIT: A retrospective chart review**
Young Shil Park¹, Taiju Hwang², Sang Kyu Park³, Ki-Young Yoo⁴, Aeran Jung⁵, Eun Jin Choi^{6*}
¹Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea
²Korea Hemophilia Foundation Clinic, Gwangju, Republic of Korea
³Korea Hemophilia Foundation Clinic, Busan, Republic of Korea
⁴Korea Hemophilia Foundation Clinic, Seoul, Republic of Korea
⁵Medical Affairs, Takeda Pharmaceuticals Korea Co., Ltd., Seoul, Republic of Korea
⁶Department of Pediatrics, Daegu Catholic University Medical Center, Daegu, Republic of Korea

POSTER LIST

- PP12-11** **Heparin-calibrated anti-factor Xa assay for the measurement of direct anticoagulant such as apixaban, rivaroxaban and edoxaban**
Hyunjung Kim^{1*}, Hyojin Chae¹, Yeongsic Kim¹, Hey Kyung Lee¹
¹Laboratory Medicine, Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
- PP12-12** **Beneficial role of moringa oleifera leaves extract in a rat model of deep vein thrombosis**
Pardeep Kumar^{1*}, Vinod Sharma¹
¹Applied Sciences, Shri Maha Maya Vaishnav Devi Research Institute, New Delhi, India
- PP12-13** **Acquired hemophilia A in an adult female without familial predisposition: A one-in-a-million rarity case report with review of the literature**
Lia Dia Farida^{2*}, Iis Novianti Rosyida¹, Herwindo Pudjo Brahmantyo¹
¹Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Saiful Anwar General Hospital/Brawijaya University, Malang, East Java, Indonesia
²Master Program in Biomedical Science, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia
- PP12-14** **Treatment of bleeding episodes with efanesoctocog alfa in patients with severe haemophilia A in the phase 3 XTEND-1 study**
 Angela C Weyand^{1*}, Sandrine Meunier², Kagehiro Amano³, Linda Bystricka⁴, Graham Neill⁵, Lydia Abad-Franch⁶, Annemieke Willemze⁷, Alberto Tosetto⁸, Sun A Lee⁹
¹Division of Hematology/Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, United States
²Clinical Hemostasis Unit, Civil Hospices of Lyon, Eastern University Hospital Group, Bron, France
³Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan
⁴Medical Program Lead Hemophilia, Sobi, Stockholm, Sweden
⁵Global Medical Hemophilia, Sanofi, Reading, United Kingdom
⁶Head of Research and Development and Medical Affairs, Sobi, Basel, Switzerland
⁷Hemophilia Cluster, Sanofi, Amsterdam, Netherlands
⁸Hemophilia and Thrombosis Center, Hematology Department, San Bortolo Hospital, Vicenza, Italy
⁹RBD Medical, Sanofi, Seoul, Republic of Korea

POSTER LIST

PP12-15

Change in hemophilia joint health score (HJHS) during the phase 3 XTEND-1 study of efanesoctocog alfa in patients with severe hemophilia A

Annette Von Drygalski^{1*}, Christoph Konigs², Chiai Nagae³, Jennifer Dumont⁴, Linda Bystricka⁵, Annemieke Willemze⁶, Elena Santagostino⁷, Johannes Oldenburg⁸, Sun A Lee⁹

¹Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, United States

²Department of Pediatrics and Adolescent Medicine, University Hospital Frankfurt, Goethe University, Frankfurt, Germany

³Department of Pediatrics, St Marianna University School of Medicine, Kawasaki, Japan

⁴Global Medical Hemophilia, Sanofi, Cambridge, United States

⁵Medical Program Lead Hemophilia, Sobi, Stockholm, Sweden

⁶Hemophilia Cluster, Sanofi, Amsterdam, Netherlands

⁷Global Medical Affairs and Clinical Science, Sobi, Basel, Switzerland

⁸Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany

⁹RBD Medical, Sanofi, Seoul, Republic of Korea

PP12-16

Inflammation and hypercoagulability in type 2 diabetes mellitus with chronic kidney disease

Volha Vasilkova^{1*}, Tatsiana Mokhort², Yuliya Yarets³

¹Endocrinology, Gomel State Medical University, Gomel, Belarus

²Endocrinology, Belarusian State Medical University, Minsk, Belarus

³Clinical Laboratory Medicine, The Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus

PP12-17

Diagnostic challenges and its clinical implications in women with inherited bleeding disorders

Sehar Khalig

Pathology, Foundation University Islamabad, Pakistan, Islamabad, Pakistan

PP13-1

The relationship between allogeneic hematopoietic stem cell transplantation recipients and COVID-19 vaccination: A literature review

Mutia Fudhla Karima^{1*}, Anggia Fitria Agustina²

¹Student of Internal Medicine, Universitas Islam Indonesia, Yogyakarta, Indonesia

²Internal Disease, Universitas Islam Indonesia, Yogyakarta, Indonesia

PP13-2

Risk factors for positive posttransplantation measurable residual disease in patients with acute lymphoblastic leukemia

Yuewen Wang¹, Guomei Fu¹, Lanping Xu¹, Yu Wang¹, Yifei Cheng¹, Yuanyuan Zhang¹, Xiaohui Zhang¹, Yanrong Liu¹, Kaiyan Liu¹, Xiaojun Huang¹, Yingjun Chang^{1*}

¹Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China

POSTER LIST

- PP13-3** **Effects of donor-specific anti-HLA antibodies(DSA) for primary graft failure of haploidentical hematopoietic stem cell transplantation in thalassemia major**
Jianyun Liao¹, Chaoke Bu¹, Lan He¹, Jujian He¹, Weiwei Zhang¹, Yuqian Xia¹, Yuelin He¹, Chunfu Li^{1*}
¹Nanfang-Chunfu Children's Institute of Hematology and Oncology, TaiXin Hospital, DongGuan, China
- PP13-4** **Post-transplant complications revealed by mycophenolate mofetil related transporters and metabolic enzymes gene polymorphisms in pediatric patients with hematological disorders**
Qi Ji¹, Yixin Hu¹, Minyuan Liu¹, Lixia Liu², Jiayue Qin², Shaoyan Hu^{1*}
¹Hematology and Oncology, Hematology and Oncology, Suzhou, China
²Department of Medical Affairs, Acommed Biotechnology Co., Ltd, Tianjin, China
- PP13-5** **Mesenchymal stem cells assisted successful treatment of pediatric patient with toxoplasma encephalitis after hematopoietic stem cell transplantation: A case report and literature review**
Qi Ji¹, Minyuan Liu¹, Hui Zhang¹, Shaoyan Hu^{1*}
¹Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China
- PP13-6** **Avapritinib is effective and safe for preemptive treatment in pediatric acute myeloid leukemia with t(8;21) and KIT mutation after allogeneic hematopoietic stem cell transplantation**
Qingwei Wang¹, Li Gao¹, Senlin Zhang¹, Jun Lu¹, Bohan Li¹, Jie Li¹, Yanhua Yao¹, Yixin Hu¹, Peifang Xiao¹, Shaoyan Hu^{1*}
¹Hematology and Oncology, Children's Hospital of Soochow University, No. 92, Suzhou, China
- PP13-7** **Post-transplant serum ferritin level predicts severe acute graft-versus-host disease in umbilical cord blood transplantation for acute leukemia**
Zhiqi Zhang¹, Bohan Li¹, Lu Liu¹, Xiaohuan Du¹, Ruolan Xiong¹, Jie Li¹, Yanli Miao¹, Peifang Xiao¹, Shaoyan Hu^{1*}
¹Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China
- PP13-8** **A prospective pilot study of graft-versus-host disease prophylaxis with postbiotics in allogeneic hematopoietic stem cell transplantation**
Seug Yun Yoon¹, Sun Young Jeong¹, Min-Young Lee¹, Kyoung Ha Kim¹, Namsu Lee¹, Jong-Ho Won^{1*}
¹Division of Hematology & Medical Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea

POSTER LIST

- PP13-9** **Efficiency of peripheral blood stem cell collection by Optia Spectra machine at hematologic department in Cho Ray Hospital**
Thao Nguyen Van¹, Nhu Cao Thi Bich^{1*}, Tung Tran Thanh¹, Cuong Bui Le¹, Dam Le Phuoc¹, Tung Nguyen Khac¹, Ut Nguyen Thi Be¹, San Le Thi¹, Anh Hoang Ngoc¹, Chau Le Thi Kim¹, Hanh Vo Thi Hong¹, Mai Nguyen Ngoc¹, Truc Tu Thi Thanh¹, Thoa Nguyen Thi¹
¹Hematology, Cho Ray Hospital, Ho Chi Minh, Vietnam
- PP13-10** **Level of knowledge of Filipino nurses on care of patients undergoing hematopoietic stem cell transplant**
Cherry Ann Durante^{1,2*}, Raul Jr Durante³
¹Graduate School, Emilio Aguinaldo College, Manila, Philippines
²Nursing, University of Perpetual Help - Dr Jose G Tamayo Medical University, Binan, Philippines
³Graduate School, International Graduate School of Leadership, Quezon City, Philippines
- PP13-11** **The impact of cytomegalovirus reactivation on relapse in acute leukemia patients undergoing allogeneic stem cell transplantation**
Hyunkyung Park
Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- PP13-12** **The efficacy of haploid hematopoietic stem cell transplantation in the treatment of children with Diamond-Blackfan anemia**
Lu Liu¹, Bohan Li¹, Lin Wan¹, Qi Ji¹, Shaoyan Hu^{1*}
¹Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China
- PP13-13** **Aerosolized pentamidine for pneumocystis jirovecii pneumonia prophylaxis in adult patients undergoing allogeneic hematopoietic cell transplantation**
Ga-Young Song¹, Mihee Kim¹, Seo-Yeon Ahn¹, Jae-Sook Ahn¹, Deok-Hwan Yang¹, Je-Jung Lee¹, Hyeoung-Joon Kim¹, Sung-Hoon Jung^{1*}
¹Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea
- PP14-1** **Inflammation stimulates the stem system in a model of hematopoietic ectopic foci**
Dmitriy Karpenko^{1*}, Aleksei Bgildeev¹
¹Laboratory of Epigenetic Regulation of Hematopoiesis, National Medical Research Center for Hematology, Moscow, Russian Federation

POSTER LIST

PP14-2 Administration of human tumor necrosis factor alpha to mice restores formation of ectopic foci of hematopoiesis lost by serial blood loss and results in the formation of foci of

Aleksei Bigildeev^{1*}, Dmitry Karpenko¹, Roman Mironov²

¹Laboratory of Epigenetic Regulation of Hematopoiesis, National Medical Research Center for Hematology, Moscow, Russian Federation (Russia), Moscow, Russian Federation

²Faculty of Biology, Department of Immunology, Lomonosov Moscow State University, Moscow, Russian Federation

PP14-3 Nes-GFP+ MSCs preserve functionality after bone marrow transplantation in a wild-type mice immunized vs-GFP

Dmitry Karpenko^{1*}, Nikolay Kapranov², Aleksei Bigildeev¹

¹Laboratory of Epigenetic Regulation of Hematopoiesis, National Medical Research Center for Hematology, Moscow, Russian Federation

²Laboratory of Immunophenotyping, National Medical Research Center for Hematology, Moscow, Russian Federation

PP14-4 Thioredoxin-interacting protein regulates megakaryopoiesis and platelet counts

Eunju Shin¹, Taeho Park^{1,2}, Ji-Yoon Noh^{1,2*}

¹Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea

²Department of Functional Genomics, Korea University of Science & Technology, Daejeon, Republic of Korea

PP14-5 Understanding the role of hippo signaling pathway in hematopoiesis using hematopoietic-specific MST1/2 deficiency mice model

Taeho Park^{1,2}, Inyoung Kim³, So Hee Kim^{1,2}, Chuna Kim^{1,2}, Wantae Kim³, Ji-Yoon Noh^{1,2*}

¹Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea

²Department of Functional Genomics, Korea University of Science & Technology, Daejeon, Republic of Korea

³Department of Biochemistry, Chungnam National University, Daejeon, Republic of Korea

PP15-1 Early intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome

Qi Ji¹, Yi Dong¹, Yongping Zhang¹, Xiaochen Wu¹, Zhenjiang Bai², Saihu Huang², Jian Pan³, Shuiyan Wu², Jun Lu¹, Shaoyan Hu^{1*}

¹Hematology & Oncology, Children's Hospital of Soochow University, Suzhou, China

²Pediatric Intensive Care Unit, Children's Hospital of Soochow University, Suzhou, China

³Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China

PP15-2 Non-viral engineering of off-the-shelf universal CART cells using CRISPR and transposons

Jaitip Tipanee¹, Marinee Chuah¹, Thierry Vanden Driessche^{1*}

¹Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium

POSTER LIST

- PP16-1** **Buffy coat pooled platelets: A cost-effective alternative to single donor apheresis platelets in hemato-oncology patients in Indian scenario - A randomized crossover trial**
Prateek Srivastava¹, Hari Krishan Dhawan^{2*}, Ratti Ram Sharma², Pankaj Malhotra², Shankar Prinja², Divjot Singh Lamba², Rekha Hans², Suchet Sachdev²
¹Transfusion Medicine, Medanta Hospital, Lucknow, India, India
²Transfusion Medicine, P.G.I.M.E.R, Chandigarh, India, India
- PP16-2** **Strategies in blood supply management during the COVID-19 pandemic: Experiences of local blood bank managers**
Archie Policarpio^{1,2}, Raphael Enrique Tiongco^{1,2*}, Jennifer Santillan^{1,3}, Annalyn Navarro^{1,2}
¹Graduate School, Angeles University Foundation, Angeles City, Philippines, Philippines
²College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines, Philippines
³College of Education, Angeles University Foundation, Angeles City, Philippines, Philippines
- PP16-3** **Blood supply in Central Luzon, Philippines in the context of the COVID-19 pandemic: A retrospective analysis**
Archie Policarpio^{1,2}, Raphael Enrique Tiongco^{1,2*}, Jennifer Santillan^{1,3}, Annalyn Navarro^{1,2}
¹Graduate School, Angeles University Foundation, Angeles City, Philippines, Philippines
²College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines, Philippines
³College of Education, Angeles City, Philippines, Angeles City, Philippines, Philippines
- PP16-4** **Motivators and barriers towards voluntary blood donation among Generation Z university students: Experience from a local higher education institution**
Engracia Arceo¹, Catherine Bacani¹, Miljun Catacata¹, Chastene Christopher Flake¹, Joey Kyle Mallari¹, Archie Policarpio¹, Madonna Sudio¹, Julie Ann Mercado^{1*}, Raphael Enrique Tiongco¹
¹College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines
- PP16-5** **Suggestion for optimization of CD3+T cell apheresis for CAR-T therapy: A retrospective analysis of parameters and predictive models**
Han Joo Kim¹, Kyong Suk Ryu¹, Dae-Hyun Ko^{1*}
¹Laboratory Medicine, Asan Medical Center, Seoul, Republic of Korea
- PP16-7** **Serodetection of cytomegalovirus IgG antibody among blood donors: Preliminary findings from a teaching hospital in the Philippines**
Raphael Enrique Tiongco¹, Jharianne Javate¹, Gwyneth Magday¹, Erika Paniza¹, Patrick Pascual¹, Myka Santiago¹, Charis Yandan¹, Trisha Zapanta¹, Julie Ann Mercado^{1*}
¹College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines

POSTER LIST

- PP16-8 Educational outcomes and perceptual change of medical students after visiting blood donation centers**
Junseo Lee¹, Seryeong Kim^{1*}, Sun Young Jeong², Seug Yun Yoon², Namsu Lee², Jong Ho Won², Jeong Won Shin³, Soon Hyo Kwon², Min-Young Lee², Kyoung Ha Kim²
¹College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea
²Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea
³Laboratory Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea
- PP16-9 Assessing centrifugal and membrane approaches in plasma exchange for kidney disease management: A comparative study**
Sindhu Bhargavi Akula¹, Divjot Singh Lamba^{1*}, Rekha Hans¹, Ratti Ram Sharma¹, Jasmine Sethi¹, Harbir Singh Kohli¹, Shankar Prinja¹
¹Transfusion Medicine, Post Graduate institute of Medical education and Research, Chandigarh, India
- PP16-10 Inconvenience and loss due to red cell transfusion dependence in patients with blood diseases and cancers: A patient-reported experience and outcomes study**
Eujin Na¹, Ja Min Byun², Dong-Yeop Shin², Youngil Koh², Inho Kim², Sung-Soo Yoon², Hye Yoon Park³, Junshik Hong^{2*}
¹Undergraduate Program, Seoul National University College of Medicine, Seoul, Republic of Korea
²Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
³Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea
- PP16-11 Temporal dynamics of platelet glycoprotein VI and reactive oxygen species: Insights from fresh and stored platelet concentrates**
Evana Kamarudin^{1*}, Razif Dasiman¹
¹Medical Laboratory Technology, Universiti Teknologi MARA (UiTM), Puncak Alam, Selangor, Malaysia
- PP17-1 How far we should care about education, wealth, and macroeconomic variables to prevent anemia prevalence among pregnant women?**
Ester Marnita Purba^{1*}, Rosinta Hotmaida P Purba², Ni Made Ratih Kusuma Dewi³, Helen Try Juniasti⁴
¹Civil Engineering, Alumnus Widyamataaram University, Yogyakarta, Indonesia
²Economics, Learningup Institute, Yogyakarta, Indonesia
³Economics, Astra Indonesia, Mataram, Indonesia
⁴Public Health, Cendrawasih University, Papua, Indonesia
- PP17-2 V736A (rs855791) polymorphism in the TMPRSS6 gene is associated with iron deficiency anemia development in females: A meta-analysis**
Arch Raphael Manalac^{1*}, Francheska Casupanan¹, Arlene Joy Canasa¹, Angela Mae Cuartelon¹, Justine Nicole Sison¹, Janina Carla Zapata¹, Raphael Enrique Tiongco¹
¹College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines

POSTER LIST

PP17-3 A meta-analysis on the association of gestational diabetes mellitus with tissue plasminogen activator

Arch Raphael Manalac^{1,2*}, Henry Basilio^{1,2}, Glenford Monzon^{1,2}, Joyce Gomez^{1,3}, Justine Malonzo^{1,4}, Raphael Enrique Tiongco^{1,2}, Annalyn Navarro^{1,2}

¹Graduate School, Angeles University Foundation, Angeles City, Philippines

²College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines

³Department of Clinical Pathology, Dr. Eutiquio Atanacio Jr. Memorial Hospital, Tarlac City, Philippines

⁴Laboratory Department, Immaculate Conception Polyclinic and Hospital Inc., Tarlac City, Philippines

PP17-4 Association of temperature, rainfall, and humidity with the incidence of pregnancy-related anemia in Central Luzon, Philippines

Miljun Catacata^{1*}, Ivy Cayabyab¹, Kristin Chernelle Dela Cruz¹, Mona Lisa Lacson^{1,2}, Arch Raphael Manalac¹, Julie Ann Mercado¹, Raphael Enrique Tiongco¹

¹College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines

²Center for Advanced Research and Innovation, Angeles University Foundation, Angeles City, Philippines

PP17-5 Diagnostic reliability of Mentzer index for beta-thalassemia trait: A systematic review and meta-analysis

Jose Felipe Pajarillo^{1,2}, Daniel Frederick Mallari¹, Miljun Catacata^{3*}, Jay Andrea Veal Israel⁴, Raphael Enrique Tiongco^{1,3}

¹Graduate School, Angeles University Foundation, Angeles City, Philippines

²Section of Molecular Laboratory, Cagayan Valley Medical Center, Tuguegarao City, Philippines

³College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines

⁴College of Allied Health Sciences, Cagayan State University, Tuguegarao City, Philippines

PP17-6 Hydroxyurea for improving leucocytosis with a splenectomized thalassemia patient in a resource limited setting

Jungho Suh

Internal Medicine, Hebron Medical Center and KOICA, Phnom Penh, Cambodia

PP17-7 Classification and prognostic stratification based on genomic features in myeloid dysplastic neoplasms, myeloproliferative neoplasms and their overlapping conditions

Jong-Mi Lee¹, Ginkyeng Lee², Byunggyu Bae¹, Yonggook Kim¹, Myungshin Kim^{1*}

¹Laboratory Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Corporation, PuzzleAI, Seoul, Republic of Korea

PP17-8 Epidemiology and clinical aspects of hematology malignancies in Cote d'Ivoire

Boidy Kouakou^{1*}, Alexis D Silue¹, Ismael Kamara¹, Anicet Konan¹, Ruth Dieket¹, Clotaire D Nanhio¹, Gustave K Koffi¹

¹Oncohematology, Cocody Teaching Hospital, Abidjan, Cote D'Ivoire

POSTER LIST

PP17-9

AI-powered precision: Elevating cell enumeration with innovative applications

Kodchapan Junwong¹, Gunyarat Wongsai¹, Thanyaphon Sakhamula¹, Suthasinee Jitanun³, Krai Dawtak^{1,2}, Nungruthai Nilso^{1,2*}

¹Faculty of Allied Health Sciences, Naresuan University, Phitsanulok, Thailand

²Cellular and Molecular Immunology Research Unit, Naresuan University, Phitsanulok, Thailand

³Faculty of Sciences, Naresuan University, Phitsanulok, Thailand

PP17-10

Establishment of hereditary hemolytic anemia registry in Korea

Hyoung Soo Choi^{1*}, Hee Won Chueh², Do Hyeon Lee³, Ye Jee Shim⁴, Hyery Kim⁵, Hye Lim Jung⁶, Namhee Kim⁷, Sang Mee Hwang⁸, Sang Hyuk Park⁹, Ari Ahn¹⁰, Myungshin Kim¹⁰, Young Kyung Lee¹¹, Jin Yeong Han¹², Jung Ok Hah¹³

¹Pediatrics, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

²Pediatrics, Inje University Haeundae Paik Hospital, Busan, Republic of Korea

³Clinical Research Support Center, The Korean Pediatric Hematology-Oncology Group (KPHOG), Seoul, Republic of Korea

⁴Pediatrics, Keimyung University School of Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea

⁵Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea

⁶Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

⁷Laboratory Medicine, Dong-A University College of Medicine, Busan, Republic of Korea

⁸Laboratory Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

⁹Laboratory Medicine, Ulsan University Hospital, Ulsan, Republic of Korea

¹⁰Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

¹¹Laboratory Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea

¹²Laboratory Medicine, Dong-A University College of Medicine, Busan, Republic of Korea

¹³Pediatrics, Yeungnam University College of Medicine, Daegu, Republic of Korea

PP17-11

Pro-adrenomedullin and procalcitonin as biomarkers for predicting infections and response to antimicrobial therapy in febrile neutropenic children

Jagdish Meena^{1*}, Harshita Makkar¹, Aditya Gupta¹, Ashutosh Halder¹, Rachna Seth¹

¹Pediatrics, All India Institute of Medical Sciences, New Delhi, India

POSTER LIST

PP17-12 Elevated IL-6 as a biomarker of immune reconstitution inflammatory syndrome in pediatric leukemia patients with invasive disseminated candidiasis

Yoon Kyung Cho^{1,2}, Ye Ji Kim^{1,2}, Hyun Mi Kang^{1,2}, Jae Won Yoo¹, Jae Wook Lee¹, Nack-Gyun Chung¹, Dae Chul Jeong¹, Bin Cho^{1*}

¹Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

PP17-13 Unleashing the potential of exosomal MALAT1 lncRNA in liquid biopsy: A promising approach for wilms tumor

Diwakar Sharma^{1,3}, Apoorv Singh², Christine Wilson³, Priyanka Swaroop², Sachin Kumar³, Deven-dra K. Yadav², Vishesh Jain², Sandeep Agarwala², Surender K. Sharawat³, Mohammad Husain^{1*}

¹Biotechnology, Virology and Oncology Lab, Department of Biotechnology, Jamia Millia Islamia, New Delhi, India

²Paediatric Surgery, Department of Paediatric Surgery, All India Institute of Medical Sciences, New Delhi, India

³Medical Oncology, Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

PP17-14 Clinical characteristics and management outcomes of patients with tumors of the hematopoietic and lymphoid tissues at mittaphab hospital, Vientiane Capital, Lao PDR

Phoutthasin Vongngakesone^{1*}, Phetsavanh Chanthavilay¹

¹Department of Internal Medicine, Setthathirath hospital, Vientiane capital, Lao People's Democratic Republic

PP18-1 Do gender equality on mother bargaining power really matter on the prevalence of anemia among children?

Rosinta Hotmaida P Purba^{1*}, Ni Made Ratih Kusuma Dewi², Ester Marnita Purba³, Helen Try Juniasti⁴

¹Economics, Learningup Institute, Yogyakarta, Indonesia

²Market insider & data analyst, Astra Indonesia, Mataram, Indonesia

³Civil Engineering, Alumnus Widyamatarem University, Yogyakarta, Indonesia

⁴Public Health, Cendrawasih University, Papua, Indonesia

PP18-2 Ginseng as an antidepressant to improve the quality of life in hematologic malignancies: A systematic review

Najila Disya Salsabila^{1*}, Binta Setya Febrina², Fajar Alfa Saputra³

¹Student of Internal Medicine, Universitas Islam Indonesia, Yogyakarta, Indonesia

²Psychiatric, Universitas Islam Indonesia, Yogyakarta, Indonesia

³Medical Education Unit, Universitas Islam Indonesia, Yogyakarta, Indonesia

POSTER LIST

PP18-3

Long-term outcomes of coronavirus disease 2019 and risk factors for prolonged SARS-Cov-2 infection in lymphoma patients: Multicenter, retrospective cohort study

Jung Ah Lee¹, Chang Hyup Kim¹, Min Han¹, Joon-Sup Yeom¹, Jun Yong Choi¹, Nam Su Ku¹, Su Jin Jeong¹, Jung Ho Kim¹, Jin Seok Kim², Haerim Chung², Hyunsoo Cho², Jin Young Ahn¹, Yu Ri Kim^{3*}

¹Infectious Disease, Severance Hospital, Seoul, Republic of Korea

²Hematology, Severance Hospital, Seoul, Republic of Korea

³Hematology, Gangnam Severance Hospital, Seoul, Republic of Korea

PP18-4

Role of wearable technology and Geo-fencing device in management of physiological data and quality of life relation to myelodysplastic syndrome patients

Vikas Sharma^{1,2*}, Madhu Gautam¹, Sagar Lavania²

¹Applied Sciences, IDC Research Center, Gurugram, India

²Neurology, S N Medical College And Hospital, Agra, India

MEMO

MEMO

[illegible]

The First G-CSF approved by FDA

GRASIN®

Safe and Effective
Treatment

For *all* Ages*

- Easy to Use
- Improved Stability
- Ensured Sterility



[Product Information]

상세제품정보는 QR코드 또는 식품의약품 안전처
의약품통합정보시스템 (<https://nedrug.mfds.go.kr>)을 통해
상세 제품정보를 참조하시기 바랍니다.

Kyowa KIRIN

서울특별시 강남구 논현로 400역삼동 11층(가게) 의학빌딩 930523
TEL:02-3471-4321 FAX:02-3471-4322
<https://www.kyowakirin.com/kr/>

ULTOMIRIS® is
the **Standard** of care for patients with **PNH¹**



울토미리스® 주
(라불리주입)
Product
Information

※ 보다 자세한 사항은 울토미리스®주 (라불리주입)
제품설명서 전문을 참고하시기 바랍니다.



울토미리스 주 (라불리주입)



울토미리스 주 (라불리주입)
100mg/mL

PNH, Paroxysmal Nocturnal Hemoglobinuria

1. Jang Hyeok Lee et al. The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments, Expert Review of Clinical Pharmacology 2022, Vol. 15, No. 7, 851-861

PUT YOUR
STAMP
ON CML



The First **STAMP** inhibitor¹, **SCEMBLIX**[®]

SCEMBLIX[®] demonstrated superior response rate and favorable tolerability by Specifically Targeting the ABL1 Myristoyl Pocket (STAMP) in BCR-ABL1¹³

For Adult with Ph+ CML-CP after 2 or more TKIs

- **SUPERIOR EFFICACY** (vs. bosutinib)
Nearly doubled MMR rate (25.5% vs. 13.2%) and higher CCyR¹⁴ (39.8% vs. 16.1%) at Week 24¹
Maintained higher MMR rate (37.6% vs. 15.8%) and CCyR¹⁴ (38.6% vs. 16.1%) at Week 96¹
- **FAVORABLE TOLERABILITY** (vs. bosutinib)
Tolerability profile consisted based on a longer median duration of exposure (29.7 months vs. 7.0 months) at Week 96¹⁴
Nearly 4 times lower discontinuation rate due to AEs (7.7% vs. 26.3%)¹⁴

The studies follow-up was 14.3 months (data cutoff of May 26, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

The studies follow-up was 2.3 years (data cutoff of October 2, 2022).

PRODUCT INFORMATION

Imported by Novartis
Pharmaceuticals
Singapore
11, Robinson Road, #11-01
Singapore 048565




SCEMBLIX[®]
(asciminib) (100, 400 mg tablets)

NOVARTIS

COLUMVI® Now approved in 3L+ diffuse large B-cell lymphoma¹




**Durable complete remissions achieved
with a unique T-cell engaging bispecific
antibody^{2,3}**



Indication

COLUMVI as monotherapy is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.

Dosing



COLUMVI duration of infusion

Cycles 1-2: Administer over 4 hours* | Cycles 3-12: Administer over 2 hours[†]

*Treatment with COLUMVI is recommended for a maximum of 12 cycles or until disease progression or unmanageable toxicity. Each cycle is 21 days.

[†]For patients who experience CRS with their previous dose of COLUMVI, the time of infusion may be extended up to 8 hours. At the discretion of the treating physician. If the patient experienced CRS with a previous dose, the duration of infusion should be maintained at 4 hours.

- Administer COLUMVI to well-hydrated patients. Counsel all patients on the risks, signs, and symptoms of Cytokine release syndrome (CRS) and advise to seek medical attention immediately should they experience signs and symptoms of Cytokine release syndrome (CRS).

References: 1. COLUMVI, Korean PI 2023-12-07-1.0 2. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med*. 2022;387(24):2220-2231. doi:10.1056/NEJMoa2206913. 3. Falchi L. Presented at the American Society of Clinical Oncology Annual Congress 2023, Chicago, IL, June 3-6, 2023.

*For more detailed product inquiries and to report adverse events, please contact Roche Korea (02) 3451-3600.

*The most up-to-date product information can be found on the Roche Korea website (www.roche.co.kr).

Roche Korea Company Ltd. 17th Floor GT Tower (East) 411 Seocho-Daero Seocho-Gu Seoul South Korea (06615) / Tel +82 2 3451 3600 / <https://www.roche.co.kr>

Product Information

Columvi (Glofitamab)



M-KR-0002464

MINJUVI[®]
tafasitamab | 200mg
Powder for solution for infusion

5-year follow-up analysis²

* Best ORR: 57.5% (n=46, 95% CI 45.9-68.5), CR: 41.3%, PR: 16.3%

* **Median DoR: Not Reached** (Median Follow-up: 44.0 months, 95% CI 29.9-57.0) (secondary outcome)

Patients with one pLoT had higher ORR compared with patients with ≥ 2 pLoT.²



Study design: Cohort study was open-label, multicentre, single arm. (b) Evaluating the efficacy and safety of VIMVAP in combination with remdesivir in hospitalized, followed by VIMVAP monotherapy in adults with SARS-CoV-2 after 1–3 cycles of Dexamethasone (Dex), through, with at least one oral-COVID-containing therapy. To assess long-term outcomes, updated analysis included with 335-months follow-up. Primary endpoint was ORR, defined as the proportion of complete and partial responders, assessed according to the 2020 International Working Group response criteria for management of COVID-19.

References 1. 中国疾病预防控制中心. 2022-09-04 2. Dai J et al. *Hemorrhagic fever with renal syndrome*. 2024;108(2):153-165. 3. WHO. *Global health*. October 2023

WUJI/KI and the 'triangle' design are registered trademarks of Incyte. Incyte and Incyte logo are registered trademarks of Incyte.

[illegible]



9.3 Months with Xospata

VS 5.6 Months
with salvage chemotherapy

54.3% **VS** **21.8%**
with Xoseta with salvage

21.8%
with salvage

25.5% with Xosrta **15.3%** with salvage

15.3%
with salvage

Reimbursement criteria
is expanded for all
FLT3+ R/R AML patient
from March 1st

[illegible]

Variable Dose: Intravenous solution. 100 mg/200 mL. **Usual Adult Dose:** 100 mg IV q 12 hr. **Usual Pediatric Dose:** 10 mg/kg IV q 12 hr. **Contraindications:** Hypersensitivity to the drug or any of its components. **Warnings:** **Cardiac:** Monitor for arrhythmias, including QT prolongation. **Central Nervous System:** Monitor for drowsiness, sedation, and respiratory depression. **Renal:** Monitor for renal impairment. **Hepatic:** Monitor for liver function. **Other:** Monitor for hypotension, hypoxia, and hyperkalemia. **Adverse Reactions:** Common: drowsiness, sedation, respiratory depression. Serious: cardiac arrhythmias, hypotension, hypoxia, hyperkalemia. **Drug Interactions:** Additive effects with other CNS depressants. **Pharmacology:** **Indication:** Sedation and anesthesia. **Pharmacokinetics:** **Onset of Action:** 1-2 minutes. **Duration of Action:** 1-2 hours. **Metabolism:** Hepatic. **Excretion:** Renal. **Contraindications:** Hypersensitivity to the drug or any of its components. **Warnings:** **Cardiac:** Monitor for arrhythmias, including QT prolongation. **Central Nervous System:** Monitor for drowsiness, sedation, and respiratory depression. **Renal:** Monitor for renal impairment. **Hepatic:** Monitor for liver function. **Other:** Monitor for hypotension, hypoxia, and hyperkalemia. **Adverse Reactions:** Common: drowsiness, sedation, respiratory depression. Serious: cardiac arrhythmias, hypotension, hypoxia, hyperkalemia. **Drug Interactions:** Additive effects with other CNS depressants. **Pharmacology:** **Indication:** Sedation and anesthesia. **Pharmacokinetics:** **Onset of Action:** 1-2 minutes. **Duration of Action:** 1-2 hours. **Metabolism:** Hepatic. **Excretion:** Renal.

Compositional disorders			
Leptinemia	33.7	4.1	Very common
Cholestanemia	79.9	18	Very common
Cholestasis	26.1	56	Very common
Endocrine disorders and abnormal drug metabolism			
Diabetes	36.4	0	Very common
Pancreas atrophy	26.1	4.3	Very common
Hyperkalemia	19.8	3.1	Very common
Adrenal insufficiency	2.9	0	Common
Immune system disorders			
Angioedema, idiopathic	3.8	7.8	Common
Infectious			
Septicemia, nosocomial	8.1	10.8	Very common
Septicemia, hospital-acquired	85.6	39.1	Very common
Respiratory tract infection	38.8	18	Very common
Respiratory tract infection, viral	55.6	6.5	Very common
Metabolic and nutritional disorders			
Acid-base balance, abnormal	1.5	0	Very common
Acidosis, metabolic	7.5	7.5	Very common
Alkalosis, metabolic	0.1	0.1	Very common
Malnutrition, protein	1.5	3.3	Common
Neurologic system disorders			
Convulsions	26.4	8.2	Very common
Seizures, idiopathic	24	0	Uncommon

[illegible]

iCKSH 2025

2025 KOREAN SOCIETY OF HEMATOLOGY
INTERNATIONAL CONFERENCE
& KSH 66th ANNUAL MEETING

MARCH 27 - 29, 2025
GRAND WALKERHILL HOTEL,
SEOUL, KOREA



See you at ICKSH 2025 again!



The Korean Society of Hematology
대한혈액학회

ICKSH 2024

2024 KOREAN SOCIETY OF HEMATOLOGY INTERNATIONAL CONFERENCE
& KSH 65th ANNUAL MEETING



The Korean Society of Hematology
대한혈액학회

ICKSH 2024 Secretariat: [PEOPLE-X] 1F, Haeoreum B/D 16, Yeoksam-ro 17 gil, Yeoksam-dong, Gangnam-gu, Seoul 06246, Korea
Tel. +82-2-566-5058 Fax. +82-2-566-6087 E-mail. icksh@icksh.org

Supported by



SEOUL METROPOLITAN
GOVERNMENT



KOREA
TOURISM
ORGANIZATION